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Abstract: The phosphoinositide 3-kinase (PI3K) pathway is frequently activated in human cancer and represents an at-
tractive target for therapies based on small molecule inhibitors. PI3K isoforms play an essential role in the signal trans-
duction events activated by cell surface receptors including receptor tyrosine kinases (RTKs) and G-protein-coupled re-
ceptors (GPCRs). There are eight known PI3K isoforms in humans, which have been subdivided into three classes (I-III). 
Therefore PI3Ks show considerable diversity and it remains unclear which kinases in this family should be targeted in 
cancer. The class IA of PI3K comprises the p110, p110 and p110 isoforms, which associate with activated RTKs. In 
human cancer, recent reports have described activating mutations in the PIK3CA gene encoding p110, and inactivating 
mutations in the phosphatase and tensin homologue (PTEN) gene, a tumour suppressor and antagonist of the PI3K path-
way. The PIK3CA mutations described in cancer constitutively activate p110 and, when expressed in cells drive onco-
genic transformation. Moreover, these mutations cause the constitutive activation of downstream signaling molecules such 
as Akt/protein kinase B (PKB), mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase (S6K) that is 
commonly observed in cancer cells. In addition to p110, the other isoforms of the PI3K family may also play a role in 
human cancer, although their individual functions remain to be precisely identified. In this review we will discuss the evi-
dence implicating individual PI3K isoforms in human cancer and their potential as drug targets in this context.  
Received on: July 31, 2007 - Revised on: September 22, 2007 - Accepted on: September 25, 2007 
INTRODUCTION 
  Phosphoinositide 3-kinases (PI3Ks) are a family of sig-
naling enzymes which regulate a variety of important cellu-
lar functions, including growth, cell cycle progression, apop-
tosis, migration, metabolism and vesicular trafficking [1, 2]. 
Since human cancer cells often display abnormal regulation 
of these cellular processes, the realization that PI3K signal-
ing is disrupted at multiple levels has prompted researchers 
to develop targeted therapies against individual enzymes 
involved in this signaling cascade [3-6]. In this review, we 
will first discuss the PI3K signaling pathway and its func-
tions in apoptosis, growth, cell cycle, angiogenesis, invasion 
and autophagy. We will subsequently present the main lines 
of evidence implicating genetic alterations in the PI3K sig-
naling cascade in the development of human cancer and dis-
cuss some of the strategies that have been used to develop 
new cancer therapies based on targeting PI3K isoforms. 
PI3K ACTIVATION BY RECEPTOR TYROSINE 
KINASES 
  Phosphoinositide 3-kinase (PI3K) was first described 20 
years ago as a distinct enzymatic activity associating with 
activated receptor tyrosine kinases (RTKs), such as the plate-
let-derived growth factor receptor (PDGFR) or with the 
polyoma virus middle T protein/pp60(c-src)
 complex [7-10].  
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PI3K activity was found to be elevated after cellular trans-
formation by p60(v-src) [11] or abl [12]. After biochemical 
purification [13], the fist genes encoding the bovine catalytic 
p110 and regulatory p85/ subunits of PI3K were cloned 
[14-17]. PI3K was shown to bind to activated RTKs via in-
teraction of the Src homology-2 (SH2) domains of the p85 
subunit to specific phosphotyrosine residues in the cyto-
plasmic domains of RTKs [15-22]. PI3K was then shown to 
be recruited to a broad variety of activated RTKs, including 
c-Met [23-25], c-Kit [26, 27], insulin-like growth factor-I 
receptor (IGF-IR) [28-30], insulin receptor (IR)/insulin re-
ceptor substrate-1 (IRS-1) [31-34], HER2/Neu/ErbB-2 [35], 
ErbB-3 [36-38], PDGFR [39, 40], Trk [41-43], and Flt3 [44].  
  Constitutively activated RTKs were found to be associ-
ated with PI3K, such as for c-Kit in leukemia [45], Tpr-Met 
[46] and EGFRvIII [47]. The constitutively activated BCR-
ABL tyrosine kinase fusion protein which has been shown to 
be an essential step in the pathogenesis of Philadelphia 
chromosome (Ph)-positive leukemias also associates with 
PI3K [48]. In addition, PI3K interacts with Ras and is di-
rectly activated by Ras binding to p110 [49-51]. PI3K activa-
tion by RTKs such as the PDGFR was also reported to be 
regulated by Ras [52]. It was also shown that p85 contains a 
GTPase-responsive domain and an inhibitory domain, which 
together form a molecular switch that regulates PI3K [53]. 
H-Ras and Rac1 activate PI3K by targeting the GTPase-
responsive domain [53]. The stimulatory effect of these 
molecules, however, is blocked by the inhibitory domain, 
which functions by binding to tyrosine-phosphorylated 
molecules and is neutralized by tyrosine phosphorylation 
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small GTPases on the p85 molecular switch result in synergy 
between these two classes of molecules toward the activation 
of the PI3K/Akt pathway [53]. Another study showed that 
p85 inhibits p110 activation by Ras [54]. This blockage was 
released by Tyr kinase stimulation, showing that the classical 
mechanism of class IA PI3K stimulation mediated by Tyr 
kinases also regulates Ras-induced PI3K activation [54]. At 
the same time as the genes of PI3K were cloned, it was 
shown that stimulation of cells with polypeptide growth fac-
tors such as PDGF induced the synthesis of novel second 
messengers phosphatidylinositol-3,4,5-trisphosphate (PIP3) 
and phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) [55, 
56], which were resistant to the action of phospholipase C 
(PLC) [57].  
PI3K ISOFORMS 
  A family of PI3K isoforms was subsequently cloned and 
characterized [58-60]. These enzymes are subdived in three 
classes (I-III), based on sequence homology and in vitro sub-
strate specificity. The class IA of PI3K includes p85/ and 
distinct regulatory subunits including mouse p55
PIK [61], and 
splice variants of the p85 gene such as p55 [62], p50 
[63], human p55 [64]. Moreover, in addition to p110 dis-
tinct catalytic p110 isoforms were cloned and termed p110 
[65] and p110 [66, 67].  
  G-protein-coupled receptors (GPCRs) were shown to 
activate the generation of PIP3 [68, 69], through the activa-
tion of a distinct isoform of PI3K. This distinct class IB p110 
isoform is activated by G subunits [70] and was termed 
p110 [71, 72]. The p110 isoform associates with an adap-
tor molecule (p101) contributing to its regulation by G 
subunits [72]. It should be also noted that the p110 isoform 
of class IA PI3K has also been reported to be regulated by 
G [73]. Ras activates p110 at the level of the membrane, 
by allosteric modulation and/or reorientation of the p110, 
implying that Ras can activate p110 without its membrane 
translocation [74]. This view is supported by structural work 
that has suggested binding of Ras to p110 results in a 
change in the structure of the catalytic pocket [75]. 
  A separate class II of PI3Ks was identified in Drosophila 
and mammalian cells, which is characterized by a C-terminal 
C2 domain and a substrate specificity restricted to PI and 
PI(4)P  in vitro [76-80]. This family includes the human 
PI3KC2, PI3KC2 and PI3KC2 isoforms [81-84]. 
  These class III PI3Ks are homologues of the yeast VPS34 
gene product (Vps34p) [85], which forms a complex with the 
Vps15 protein kinase and is essential for protein sorting to 
the yeast lysosome-like vacuole [86]. The human homo-
logues of Vps34p and Vps15p were subsequently cloned [87, 
88], as well as their Drosophila counterpart [89]. The human 
Vps34p was reported to associate with the trans-Golgi net-
work, a key site for the formation of transport vesicles des-
tined for different intracellular compartments [90].  
  A family of protein kinases with homology to PI3Ks was 
also cloned and characterized, including yeast target of ra-
pamycin (TOR) proteins [91, 92], and their mammalian 
homologue FRAP/RAFT1/mTOR [93-96]. This family of 
protein kinases also includes ATM, the gene product that is 
mutated in the autosomal recessive disorder ataxia telangiec-
tasia (AT) [97, 98], ATR, and DNA-dependent protein 
kinase (DNA-PK) [99]. 
STRUCTURE OF PI3K ISOFORMS 
  The crystal structure of the SH2 and SH3 domains of 
p85 was solved, providing the first insights into the mo-
lecular mechanisms of PI3K regulation by RTKs [100, 101]. 
The interaction between the p85 and p110 subunits was 
shown to involve the inter-SH2 region of p85 [102, 103] and 
the N-terminal region of p110 [104, 105]. Furthermore, the 
p85 subunit contains two proline-rich sequences in its N-
terminal region which can bind SH3 domains, such as those 
present in Src family kinases [106, 107]. Subsequently, the 
structure of the p85 breakpoint cluster region (BCR)-
homology domain was solved [108]. The BCR domain is 
responsible for the activity of GTPase-activating proteins 
(GAP) in proteins such as BCR. The X-ray crystallographic 
structure of the catalytic isoform p110 was then solved 
[109]. p110 has a modular organization centred around a 
helical-domain spine, with C2 and catalytic domains posi-
tioned to interact with phospholipid membranes, and a Ras-
binding domain placed against the catalytic domain where it 
could drive allosteric activation of the enzyme [109]. A crys-
tal structure of a p110/Ras complex was also reported [75]. 
A critical loop in the Ras binding domain positions Ras so 
that it uses its switch I and switch II regions to bind p110 
[75]. Ras also forms a direct contact with the p110 catalytic 
domain [75]. The complex with Ras shows a change in the 
PI3K conformation that may represent an allosteric compo-
nent of Ras activation. The X-ray crystallographic structures 
of p110 bound to the specific PI3K inhibitors wortmannin 
and LY294002 and to the broad-spectrum protein kinase 
inhibitors quercetin, myricetin, and staurosporine reveal how 
these compounds fit into the ATP binding pocket. With a 
nanomolar IC50, wortmannin most closely fits and fills the 
active site and induces a conformational change in the cata-
lytic domain [110]. These results provided the basis for de-
velopment of isoform-specific PI3K inhibitors with thera-
peutic potential [110]. 
PI3K SIGNALING 
  The use of mutant receptors defined for the first time a 
role for PI3K in PDGF-dependent DNA synthesis, and estab-
lished PI3K as an independent downstream mediators of 
PDGF's mitogenic signal [111]. Furthermore, a mutant CSF-
1R with a mutation in the PI3K-binding site had impaired 
ability to transduce signals controlling changes in morphol-
ogy and increased cell growth [112]. The PI3K binding sites 
also appeared both necessary and sufficient for the normal 
endocytic trafficking of the activated PDGFR [113]. A 
PDGFR mutant in which both p85-binding sites were mu-
tated failed to stimulate membrane ruffling and chemotaxis, 
suggesting a role for PI3K in these responses [114, 115].  
  Pharmacological inhibitors of PI3K were instrumental in 
elucidating the role of the enzyme in cellular signaling 
events. These inhibitors include quercetin analogs, the most 
widely used being LY294002 [116], as well as the microbial 
product wortmannin [117-119]. In addition to their effects  
on PI3K isoforms, LY294002 and wortmannin also inhibit  
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ATM and DNA-PK [121]. Studies with wortmannin and 
LY294002 uncovered a role for PI3K in activation of 
p70(S6K) by insulin and PDGF [122-125], as well as in the 
inactivation of glycogen synthase kinase-3 (GSK-3) [126]. 
Subsequently, PI3K was shown to be essential in the activa-
tion of the proto-oncogene Akt (or protein kinase B (PKB)) 
by PDGF [127] and other growth factors [128, 129]. These 
results were confirmed by the observation that transfection 
of membrane-targeted p110 was sufficient to trigger down-
stream responses characteristic of growth factor action, in-
cluding the stimulation of p70(S6K) and Akt [130, 131]. The 
phospholipids products of PI3K, initially PI(3,4)P2, were 
shown to directly activate Akt by binding to its pleckstrin 
homology (PH) domain [132, 133]. PH domains were recog-
nized to be modular domains with the ability to specifically 
bind to the lipid products of PI3K, including PIP3 [134]. 
PI3K activity was also required for phosphorylation of both 
Thr308 and Ser473 activation sites of Akt [135]. The kinase 
that phosphorylates Akt was then purified, cloned and shown 
to phosphorylate Akt1 at Thr308 and increase its activity 
[136-138]. It was found that only PI(3,4,5)P3 or PI(3,4)P2 
were effective in potently activating the kinase, which was 
termed PI(3,4,5)P3-dependent protein kinase-1 (PDK1) 
[136]. PDK1 is the protein kinase that mediates the activa-
tion of Akt/PKB by insulin and growth factors [139]. PDK1 
therefore plays a key role in mediating many of the actions 
of the second messengers produced by PI3K. In response to 
PDGF, binding of PI(3,4,5)P3 and/or PI(3,4)P2 to the PH 
domain of PDK-1 causes its translocation to the plasma 
membrane where it co-localises with Akt/PKB, significantly 
contributing to the scale of Akt/PKB activation [139, 140] 
(Fig. 1). The identification of the kinase that phosphorylates 
the Akt Ser473 was achieved only in the last few years 
[141]. The complex of the mammalian target of rapamycin 
(mTOR) and Rictor was shown to be essential for this crucial 
phosphorylation step in Akt by several groups [141, 142].  
  In addition to its role in Akt activation, PDK1 was also 
shown to be responsible for the regulation of other protein 
kinases [143, 144]. PDK1 phosphorylated the activation loop 
sites of PKC and PKC in vitro and in a PI3K-dependent 
manner  in vivo [145, 146]. Several members of the PKC 
family tested formed complexes with PDK1 [145]. Serum 
and glucocorticoid-inducible kinase (SGK) was also shown 
to be a target of PI3K/PDK1 [147, 148]. A regulatory link 
between p70(S6K) and PDK1 was also described, since 
PDK1 selectively phosphorylates and activated p70(S6K) in 
vitro and in vivo [149, 150].  
  In addition, PI3K was reported to be involved in the acti-
vation of several other protein kinases, including c-Jun N-
terminal kinase (JNK) by EGF [151]. Bruton's tyrosine 
kinase (Btk), which has a PH domain that can bind PIP3 
[152], was described as a downstream target of PI3K (p110) 
[153]. Etk/Bmx a member of the Btk tyrosine kinase family 
that contains a PH domain is also involved in the PI3K 
pathway [154]. The Tec family non-receptor tyrosine kinases 
were shown to be regulated by PIP3 interacting with its PH 
domain [155]. Activation of PI3K caused phospholipase C- 
(PLC-) PH domain-mediated membrane targeting and PLC-
 activation [156, 157]. Integrin-linked kinase (ILK) was also 
proposed to be a receptor-proximal effector for the PI3K-
dependent, extracellular matrix and growth factor mediated, 
activation of Akt, and inhibition of GSK-3 [158]. RNA inter-
ference (RNAi) as well as conditional knock-out of ILK had 
no effect on phosphorylation of Akt on Thr-308 but resulted 
in almost complete inhibition of phosphorylation on Ser-473 
and significant inhibition of Akt activity, accompanied by 
significant stimulation of apoptosis [159]. In addition, Raf-1 
activation by Ras was shown to be achieved through a com-
bination of both physical interaction and indirect mecha-
nisms involving the activation of PI3K as a second Ras ef-
fector, which directs p21-activated kinase (PAK)-mediated 
regulatory phosphorylation of Raf-1 [160]. Phosphorylation 
of Raf-1 on Ser338 through PI3K and Pak was also shown to 
provide a co-stimulatory signal which together with Ras 
leads to strong activation of Raf-1 kinase activity by in-
tegrins [161]. 
  A consensus sequence which predicts high-affinity bind-
ing of PH domains to PtdIns(3, 4)P2 and/or PtdIns(3,4,5)P3 
was proposed, and several new PH domain-containing pro-
teins that directly bind PI3K products were identified, in-
cluding Gab1, Dos, myosinX, and Sbf1 [162], GAP1(m) a 
member of the GAP1 family of Ras GTPase-activating pro-
teins (GAPs) [163], DAPP1 [164], Tec family tyrosine kina-
ses [165], ARAP3 [166], and P-Rex1, a Rac activator [167].  
PI3K /Akt SIGNALING AND APOPTOSIS 
  The involvement of PI3K in prevention of apoptosis by 
polypeptide growth factor receptors was first described by 
studies using both wortmannin and LY294002 [168-170]. 
Experiments with pharmacological inhibitors, as well as ex-
pression of wild-type and dominant-inhibitory forms of Akt, 
demonstrated that Akt mediates PI3K-dependent survival 
[171-175]. These findings were supported by studies show-
ing that Ras activation of PI3K suppresses c-Myc-induced 
apoptosis through the activation of Akt but not p70(S6K) 
[176]. UV-B light-induced-apoptosis was also prevented by 
IGF-I/PI3K/Akt signaling [177] and interleukin-3-dependent 
survival of hematopoietic cells required PI3K/Akt signaling 
[178]. Neuronal survival in the absence of nerve growth fac-
tor (NGF) was promoted by PI3K/Akt [179] and it was also 
shown that Akt can transduce a survival signal for differenti-
ating neuronal cells through a mechanism that is independent 
of induction of Bcl-2 or Bcl-XL, or inhibition of JNK activity 
[180]. PI3K acting through Akt was implicated as a key me-
diator of the aberrant survival of Ras-transformed epithelial 
cells in the absence of attachment, and as a mediator of ma-
trix-induced survival of normal epithelial cells [181].  
  Some of the proposed mechanisms for the antiapoptotic 
effect of activated Akt include the inhibition of proapoptotic 
Bcl-2 family proteins, downregulation of death receptors, 
and enhancement of the glycolytic rate [182]. There exists a 
large panel of Akt substrates which mediate its effects on 
cellular responses, including apoptosis, growth and cell cycle 
regulation [173-175] (Fig. 1). The Akt targets identified so 
far include BAD [183-185], the FOXO (Forkhead Box, sub-
group O) family of transcription factors [186-189] and AFX 
[190], glycogen synthase kinase-3 (GSK-3) [139, 191, 192], 
p27(Kip1) [193, 194], Mdm2 [195], endothelial NO synthase 
(eNOS) [196, 197], cyclic nucleotide phosphodiesterase 3B 
isoform (PDE3B)[198], Raf [199, 200], apoptosis signal-
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[202], the nuclear factor CREB [203], the p300 transcrip-
tional coactivator [204] and E2F [205, 206].  
  In addition, it was shown that Akt can regulate signaling 
pathways that lead to induction of the NF-B family of tran-
scription factors [207-209]. This induction occurred at the 
level of degradation of the NF-B inhibitor IB [207]. 
PDGF was also shown to activate NF-B through Ras and 
PI3K to Akt and the IB kinase (IKK) [208]. Upon PDGF 
stimulation, Akt transiently associated in vivo with IKK and 
induced IKK activation [208]. Akt was reported to stimulate 
NF-B predominantly by up-regulating of the transactivation 
potential of the p65 subunit of NF-B [210]. Survivin, a 
member of the inhibitors-of-apoptosis gene family, is ex-
pressed in a cell-cycle-dependent manner in all the most 
common cancers but not in normal differentiated adult tis-
sues [211]. Hematopoietic cytokines were reported to exert 
their antiapoptotic and mitogenic effects, at least in part, by 
increasing survivin levels, which was dependent on PI3K 
[211]. It was also shown that both vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor 
significantly reduce the pro-apoptotic potency of chemother-
apy on endothelial cells, a response, which PI3K-dependent 
and could be recapitulated by over-expressing the dominant-
active form of Akt [212]. Work by others showed that the 
anti-apoptotic effects of IL-6 were mediated, at least in part, 
by Mcl-1 (Bcl-2 family member) expression and that the 
response occured mainly through the PI3K/Akt pathway 
[213]. It was reported that apoptotic cell death of PTEN-
deficient prostate cancer cells induced by LY294002 or ex-
pression of wild type PTEN can be abrogated by disrupting 
Fas/Fas ligand (FasL) interactions [214]. These data showed 
that apoptosis induced by blockade of the PI3K pathway in 
prostate tumor cells is mediated by an autocrine Fas/FasL 
apoptotic mechanism and that the Fas apoptotic pathway is 
both necessary and sufficient to mediate apoptosis by PI3K 
inhibition [214]. 
PI3K SIGNALING AND GROWTH CONTROL 
  Signaling networks that promote cell growth are fre-








Fig. (1). Signalling through the phosphatidylinositol 3-kinase (PI3K) affects cell growth, apoptosis and cell cycle regulation. The 
PI3K/Akt related pathways have a key role in initiating intracellular signalling cascades subsequent to the activation of membrane tyrosine 
kinases. The PI3K phosphorylates phosphatidylinositol-biphosphates (PIP2), generating phosphatidylinositol-triphosphates (PIP3). PIP3 act as 
docking sites for Akt and PDK at the plasma membrane. Upon phosphorylation by PDK, AKT becomes activated and phosphorylates in turn 
several downstream proteins, regulating cell growth, survival, apoptosis and cell cycle. PTEN, phosphatase and tensin homolog deleted on 
chromosome 10; PDK, phosphoinositide-dependent kinases; GSK3, glycogen synthase kinase-3; MDM2, murine double minute; FKHR, 
forkhead; NF-B, nuclear facto B; Rheb, Ras homologue enriched in the brain; TSC1, TSC2, tuberous sclerosis complex 1 and 2; mTOR, 
mammalian target of rapamycin; 4EBP1, eukaryotic translation initiation factor 4E binding protein; S6K, S6 kinase. The Phosphoinositide 3-Kinase Pathway in Human Cancer  Current Genomics, 2007, Vol. 8, No. 5    275 
which converges on effectors such as eIF4E-binding pro-
teins-1 (4E-BP1) and p70(S6K), leads to growth by promot-
ing protein synthesis [215]. In particular, a tumor suppressor 
complex whose function is lost in tuberous sclerosis patients 
regulates the nutrient signal carried by the critical signaling 
protein TOR to the effectors 4E-BP1 and p70(S6K) [215].  
  It was initially demonstrated that the PI3K/Akt signaling 
pathway, in concert with FRAP/mTOR, induces the phos-
phorylation and inactivation of the translational repressor, 
the 4E-BP1 [216] and activation of p70(S6K) [217, 218]. 
Further work showed that mTOR signals downstream to at 
least two independent targets, S6K1 and 4E-BP1/eIF4E that 
function in translational control to regulate mammalian cell 
size [219]. The tuberous sclerosis complex-2 (TSC2) gene 
product, tuberin, is as a target of Akt [220-223]. Normal cel-
lular functions of hamartin and tuberin, encoded by the 
TSC1 and TSC2 tumor suppressor genes, are closely related 
to their direct interactions. Tuberous sclerosis (TSC) is an 
autosomal dominant disorder characterized by the formation 
of hamartomas in a wide range of human tissues [224]. It 
was demonstrated that, upon activation of PI3K, tuberin is 
phosphorylated on consensus recognition sites for PI3K-
dependent S/T kinases [220]. Moreover, Akt/PKB could 
phosphorylate tuberin in vitro and in vivo [220]. It was also 
shown that S939 and T1462 of tuberin are PI3K-regulated 
phosphorylation sites and that T1462 is constitutively phos-
phorylated in PTEN (-/-) tumor-derived cell lines [220]. Fi-
nally, a tuberin mutant lacking the major PI3K-dependent 
phosphorylation sites blocked the activation of S6K1, sug-
gesting a means by which the PI3K-Akt pathway regulates 
S6K1 activity [220]. Other reports showed that TSC1-TSC2 
inhibits the p70(S6K) and activates the 4E-BP1, which was 
mediated by inhibition of mTOR [220, 222]. Furthermore, 
Tsc2 was shown to be directly phosphorylated by Akt. Tsc2 
was inactivated by Akt-dependent phosphorylation, which 
destabilizes Tsc2 and disrupts its interaction with Tsc1 
[222]. It was shown that TSC1 and TSC2 antagonize the 
amino acid-TOR signaling pathway [221]. Tsc1 and Tsc2 
could physically associate with TOR and function upstream 
of TOR genetically. In Drosophila melanogaster and mam-
malian cells, loss of TSC1 and TSC2 resulted in a TOR-
dependent increase of S6K activity [225]. Furthermore, al-
though S6K is normally inactivated in animal cells in re-
sponse to amino acid starvation, loss of TSC1-TSC2 renders 
cells resistant to amino acid starvation. It was thus proposed 
that the Tsc1-Tsc2 complex antagonizes the TOR-mediated 
response to amino acid availability [225]. These studies 
identified Tsc1 and Tsc2 as regulators of the amino acid-
TOR pathway and provide a new paradigm for how proteins 
involved in nutrient sensing function as tumor suppressors 
[221, 225]. Work by another group showed that insulin or 
IGF-I stimulated phosphorylation of tuberin, which was in-
hibited by the PI3K inhibitor LY294002 [226]. Expression 
of constitutively active PI3K or active Akt induced tuberin 
phosphorylation. It was further demonstrated that Akt/PKB 
associates with hamartin-tuberin complexes, promoting 
phosphorylation of tuberin and increased degradation of ha-
martin-tuberin complexes [226]. The ability to form com-
plexes, however, was not blocked. Akt also inhibited tu-
berin-mediated degradation of p27(KIP1), thereby promoting  
 
CDK2 activity and cellular proliferation [226]. These results 
confirmed that tuberin is a direct physiological substrate of 
Akt and that phosphorylation of tuberin by PI3K/Akt is a 
major mechanism controlling hamartin-tuberin function 
[226]. 
  Further work showed that TSC1/2 is a GAP for the small 
GTPase Rheb and that insulin-mediated Rheb activation is 
PI3K-dependent [227-229]. Rheb over-expression induced 
S6K1 phosphorylation and inhibited Akt phosphorylation, as 
did loss-of-function mutations in TSC1/2 [227]. Co-expres-
sion of a human TSC2 harboring a disease-associated point 
mutation in the GAP domain, failed to stimulate Rheb 
GTPase activity or block Rheb activation of S6K1 [227, 
229]. A screen for novel regulators of growth identified 
Rheb (Ras homologue enriched in brain), a member of the 
Ras superfamily of GTP-binding proteins [228]. Increased 
levels of Rheb in Drosophila melanogaster promoted cell 
growth and alter cell cycle kinetics in multiple tissues. In 
mitotic tissues, overexpression of Rheb accelerates passage 
through G1-S phase without affecting rates of cell division 
[228]. Genetic and biochemical tests indicated that Rheb 
functions in the insulin signalling pathway downstream of 
Tsc1-Tsc2 and upstream of TOR [228]. In another study, 
mutations in the Drosophila melanogaster Rheb gene were 
isolated as growth-inhibitors, whereas over-expression of 
Rheb promoted cell growth [230]. Genetic and biochemical 
analyses suggest that Rheb functions downstream of the tu-
mour suppressors Tsc1-Tsc2 in the TOR signalling pathway 
to control growth, and that a major effector of Rheb function 
is S6K [230, 231]. 
  It was reported that Akt activation causes proteasomal 
degradation of substrates that control cell growth and sur-
vival [232]. Expression of activated Akt triggered protea-
some-dependent declines in the protein levels of the Akt 
substrates tuberin, FOXO1, and FOXO3a [232]. The addi-
tion of proteasome inhibitors stabilized the phosphorylated 
forms of multiple Akt substrates, including tuberin and 
FOXO proteins [232]. Activation of Akt also triggered the 
ubiquitination of several proteins containing phosphorylated 
Akt substrate motifs [232]. Together the data indicate that 
activated Akt stimulates proteasomal degradation of its sub-
strates and suggest that Akt-dependent cell growth and sur-
vival are induced through the degradation of negative regula-
tors of these processes [232]. It has been shown that FKHR 
is phosphorylated via insulin or growth factor signaling cas-
cades, resulting in its cytoplasmic retention and the repres-
sion of target gene expression. Insulin treatment was shown 
to decrease endogenous FKHR proteins in HepG2 cells, 
which was inhibited by proteasome inhibitors [233]. FKHR 
was ubiquitinated in vivo and in vitro, and insulin enhances 
the ubiquitination in the cells [233]. In addition, the signal to 
FKHR degradation from insulin was shown to be mediated 
by the PI3K pathway, and the mutation of FKHR at the ser-
ine or threonine residues phosphorylated by Akt inhibited the 
ubiquitination  in vivo and in vitro [233]. Another report 
showed that FoxO1 expression is constitutively suppressed 
in chicken embryo fibroblasts transformed by P3k or Akt 
[234]. In this system, phosphorylation-dependent degrada-
tion of FoxO1 by means of proteasomes played a role in on-
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  It was shown that Tsc1-Tsc2 is required for insulin sig-
naling to PI3K [235, 236] by restraining the activity of 
S6K1, which when activated inactivates insulin receptor sub-
strate (IRS) function, via repression of IRS-1 gene expres-
sion and via direct phosphorylation of IRS-1 [235]. These 
results suggested that the low malignant potential of tumors 
arising from TSC1-2 dysfunction may be explained by the 
failure of TSC mutant cells to activate PI3K and its down-
stream effectors [235, 236]. 
PI3K IN CELL CYCLE CONTROL 
  Cell cycle progression is a tightly controlled process. To 
initiate cell division, mitogens trigger a number of early sig-
nals that promote the G(0)-G(1) transition by inducing cell 
growth and the activation of G(1) cyclins. Activation of cy-
clin E/cdk2 (cyclin-dependent kinase 2) at the end of G(1) is 
then required to trigger DNA synthesis (S phase entry). 
Among the early signals induced by mitogens, activation of 
PI3K appears essential to induce cell cycle entry, as it regu-
lates cell growth signalling pathways (see previous section), 
which in turn determine the rate of cell cycle progression. 
Another mechanisms by which PI3K and its downstream 
effector Akt regulate cell cycle entry is by inactivation of the 
FOXO transcription factors, which induce expression of qui-
escence genes such as those encoding p27(Kip), p130 and 
cyclin G2 [237]. PI3K/FOXO then work as a complementary 
switch: when PI3K is active, FOXO transcription factors are 
inactive [237]. The switch is turned on and off at different 
phases of the cell cycle, thus regulating cell cycle progres-
sion. Akt triggers a network that positively regulates G1/S 
cell cycle progression through inactivation of GSK3, lead-
ing to increased cyclin D1, and inhibition of Forkhead family 
transcription factors and the tumor suppressor tuberin 
(TSC2), leading to reduction of p27(Kip1) [238]. The identi-
fication of p21Waf1/Cip1 and p27Kip1 as novel substrates 
of Akt provided new insights into mechanisms whereby hy-
peractivation of this lipid signaling pathway may lead to cell 
cycle deregulation in human cancers [238]. 
  The PI3K/Akt pathway must be activated in G1 to inacti-
vate forkhead transcription factors and allow cell cycle entry. 
It was subsequently shown that attenuation of the PI3K/Akt 
pathway is required to allow transcriptional activation of 
FOXO in G2 [239]. FOXO activity in G2 controls mammal-
ian cell cycle termination, as interference with FOXO tran-
scriptional activation by disrupting PI3K/Akt downregula-
tion, or by expressing a transcriptionally inactive FOXO 
mutant, induces cell accumulation in G2/M, defective cyto-
kinesis, and delayed transition from M to G1 of the cell cycle 
[239]. It was demonstrated that FOXO regulate expression of 
mitotic genes such as cyclin B and polo-like kinase (Plk) 
[239]. These results supported the important role of forkhead 
transcription factors in the control of mammalian cell cycle 
completion, and suggest that efficient execution of the mi-
totic programme depends on downregulation of PI3K/Akt 
and consequent induction of FOXO transcriptional activity 
[239]. 
PI3K SIGNALING IN MIGRATION AND INVASION 
  Migration of cancer cells is one of the key factors re-
sponsible for cancer metastasis. The elucidation of mecha- 
 
nisms responsible for the highly invasive potential of cancer 
cells can help to identify specific targets for the treatment of 
cancer patients. Highly invasive cancers are usually char- 
acterized by aberrant activity of specific intra- or extracellu-
lar molecules such as protein kinases, phosphatases, trans- 
criptional factors, proteolytic enzymes, and others. There-
fore, inhibition of specific target molecules in common sig-
naling pathway(s) responsible for metastatic spread can have 
potential clinical relevance.  
  The first identified downstream target of PI3K in PDGF-
stimulated membrane ruffling was Rac [240, 241]. Class IA 
PI3Ks are implicated in many cellular responses controlled 
by receptor tyrosine kinases (RTKs), including actin cy-
toskeletal remodeling. Within this pathway, Rac is a key 
downstream target/effector of PI3K. One possible candidate 
for this function is the Rac-activating complex Eps8-Abi1-
Sos-1, which possesses Rac-specific guanine nucleotide ex-
change factor (GEF) activity [242]. It was shown that Abi1 
(also known as E3b1) recruits PI3K, via p85, into a multi-
molecular signaling complex that includes Eps8 and Sos-1 
[242]. The recruitment of p85 to the Eps8-Abi1-Sos-1 com-
plex and PIP3, co-operate to unmask its Rac-GEF activity in 
vitro [242]. Moreover, they are indispensable for the activa-
tion of Rac and Rac-dependent actin remodeling in vivo 
[242]. Upon growth factor stimulation, endogenous p85 and 
Abi1 consistently colocalized into membrane ruffles, and 
cells lacking p85 failed to support Abi1-dependent Rac acti-
vation [242]. 
  Direct PI3K activation was sufficient to disrupt epithelial 
polarization and induce cell migration and invasion [243]. 
PI3K inhibition also disrupted actin structures, suggesting 
that activation of PI3K alters actin organization, leading to 
increased motility and invasiveness [243]. Integrin-mediated 
activation of PI3K was shown to promote carcinoma inva-
sion by targeting Rac [244]. Vav, a guanosine diphosphate 
(GDP)-guanosine triphosphate (GTP) exchange factor (GEF) 
for Rac that stimulates the exchange of bound GDP for GTP, 
bound to and was directly controlled by substrates and prod-
ucts of PI3K [245]. PI3K also acts upstream of Tiam1, an 
activator of Rac [246]. Akt/PKB potently promoted invasion 
of highly metastatic cells, by increasing cell motility and 
matrix metalloproteinase-9 (MMP-9) production, in a man-
ner highly dependent on its kinase activity and membrane-
translocating ability [247]. The increase in MMP-9 produc-
tion was mediated by activation of NF-B transcriptional 
activity by Akt/PKB [247]. However, Akt/PKB did not af-
fect the cell-cell or cell-matrix adhesion properties of the 
cells. These findings thus established Akt/PKB as a major 
factor in the invasive abilities of cancer cells [247]. Another 
study showed that PI3K is constitutively active and controls 
cell motility of highly invasive breast cancer cells by the 
activation of transcription factor, NF-B [248]. The 
urokinase-type plasminogen activator (uPA) promoter con-
tains an NF-B binding site, and uPA expression in MDA-
MB-231 cells was induced by the constitutively active NF-
B [248]. Cell migration was inhibited by overexpression of 
a dominant negative p85, as well as by pretreatment of 
cells with wortmannin and LY294002 [248]. Highly invasive 
MDA-MB-231 cells constitutively secreted uPA in amounts 
significantly higher than poorly invasive MCF-7 cells [248].  
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Furthermore, inhibition of NF-B markedly attenuated en-
dogenous migration, and inhibition of PI3K and NF-B re-
duced secretion of uPA [248]. These data suggest a link be-
tween constitutively active PI3K, NF-B, and secretion of 
uPA, which is responsible for the migration of highly inva-
sive breast cancer cells [248]. In another study, constitutive 
activation of Akt was identified in breast cancer cells, while 
benign breast epithelial cell lines were immortalized through 
pathways that are independent of the EGF/PI3K/Akt kinase 
cascade, but this was not associated with invasiveness [249]. 
Transfection of constitutively active Akt caused accelerated 
cell division and osteopontin expression [249]. Conversely, 
dominant-negative Akt kinase slows cell cycle progression 
and suppresses osteopontin expression [249]. The manipula-
tion of osteopontin expression in this setting by transfection 
of the gene or its antisense did not affect the growth rate of 
the cells but altered cell motility and anchorage independ-
ence [249]. Therefore, Akt kinase was postulated to activate 
two distinct genetic programs: the program of growth and 
survival and the program of invasiveness and anchorage in-
dependence, which is mediated by osteopontin [249]. These 
studies define Akt kinase as a molecular bridge between cell 
cycle progression and dissemination. In colorectal cancer, 
another group investigated the effect of inhibiting the 
PI3K/Akt/IKK pathway in regulating the inappropriate 
constitutive activation of NF-B and -catenin [250]. Induc-
ible expression of either dominant-negative IKK or PTEN 
strongly inhibited both the constitutive NF-B- and -
catenin-dependent promoter and endogenous gene activation 
[250]. Targeted array-based gene expression analysis of this 
inducible system reveals that many of the genes downregu-
lated upon inhibition of this pathway were involved in tumor 
angiogenesis and metastasis [250]. 
PI3K IN ANGIOGENESIS 
  PI3K signaling plays a key role in tumor angiogenesis, 
the development of new blood vessels. Hypoxia develops in 
the majority of solid tumors due to the inability of the exist-
ing vascular system to supply the growing tumor mass with 
adequate amounts of oxygen [251]. A large body of clinical 
evidence suggests that intratumoral hypoxia correlates with 
the elevated aggressive behavior of cancer cells and their 
resistance to therapy, leading to poor patient prognoses 
[251]. Hypoxia-inducible factor 1 (HIF-1) is a transcriptional 
activator that functions as a master regulator of O2 homeo-
stasis [252]. HIF-1 target genes encode proteins that increase 
O2 delivery and mediate adaptive responses to O2 depriva-
tion [252]. Several HIF-1 targets are known, including the 
gene encoding vascular endothelial growth factor (VEGF). 
HIF-1 activity is regulated by the cellular O2 concentration 
and by the major growth factor-stimulated signal transduc-
tion pathways [252]. In human cancer cells, both intratu-
moral hypoxia and genetic alterations affecting signal trans-
duction pathways lead to increased HIF-1 activity, which 
promotes angiogenesis, metabolic adaptation, and other criti-
cal aspects of tumor progression [252, 253]. HIF-1 is a tran-
scriptional activator composed of HIF-1 and HIF-1 
subunits [253, 254]. Under hypoxic conditions, HIF-1 ex-
pression increases as a result of decreased ubiquitination and 
degradation [254]. The tumor suppressors VHL (von Hippel-
Lindau protein) and p53 target HIF-1 for ubiquitination 
such that their inactivation in tumor cells increases the half-
life of HIF-1 [254]. Increased PI3K and Akt or decreased 
PTEN activity in cancer cells were also shown to increase 
HIF-1 [255]. A further study observed that hypoxic induc-
tion of HIF-1 protein was decreased by serum deprivation 
in carcinoma cells under low oxygen tension [256]. Over-
expression of dominant-active Akt1 restored HIF-1 expres-
sion, whereas inhibition of PI3K activity reduced hypoxic 
HIF-1 protein levels [256]. An immunohistochemical 
analysis of human breast cancers revealed that lack of Akt1 
phosphorylation correlates with low HIF-1 levels [256]. 
The angiogenic switch in Ras-transformed cells is promoted 
by the tumor microenvironment through the induction of the 
angiogenic mitogen, VEGF. It was shown that hypoxia 
modulates VEGF induction in Ras-transformed cells through 
the activation of a stress inducible PI3K/Akt pathway and 
the HIF-1 transcriptional response element [257]. Hypoxia 
was reported to activate a growth factor receptor (PDGFR)/ 
PI3K/Akt cascade that leads to GSK-3 inactivation, and thus 
impact on cell survival, proliferation, and metabolism [258]. 
It was also reported that under hypoxic conditions, rat pheo-
chromocytoma PC12 cells are resistant to apoptosis induced 
by serum withdrawal and chemotherapy treatment. The hy-
poxia-dependent protection from apoptosis correlated with 
activation of the PI3K/Akt pathway [259]. In another study, 
insulin and epidermal growth factor or an inactivating muta-
tion in the tumor suppressor PTEN specifically increased the 
protein levels of HIF-1, but not of HIF-1 in human cancer 
cell lines [260]. This specific elevation of HIF-1 protein 
expression required PI3K signaling [260]. Another study 
examined the involvement of FOXO4 (also known as AFX), 
a member of the forkhead transcription factor superfamily 
that is negatively regulated by the PI3K/Akt pathway, in the 
regulation of HIF-1 protein expression [261]. Nuclear ex-
pression of FOXO4 resulted in the suppression of various 
responses to hypoxia, including decreased VEGF [261]. In-
terestingly, FOXO4 down-regulated the HIF-1 protein lev-
els, consistent with the lack of hypoxia responsiveness [261]. 
In another study, the linkage between mTOR and HIF-1 in 
PC-3 prostate cancer cells treated during hypoxia was further 
explored [262]. Pretreatment of PC-3 cells with the mTOR 
inhibitor, rapamycin, inhibited both the accumulation of 
HIF-1 and HIF-1-dependent transcription induced by hy-
poxia [262]. Further work pinpointed the oxygen-dependent 
degradation domain as a critical target for the rapamycin-
sensitive, mTOR-dependent signaling pathway leading to 
HIF-1 stabilization by hypoxia-inducing agents [262]. 
These studies position mTOR as an upstream activator of 
HIF-1 function in cancer cells and suggest that the anti-
tumor activity of rapamycin is mediated, in part, through the 
inhibition of cellular responses to hypoxic stress [262]. 
  Tumor angiogenesis is postulated to be regulated by the 
balance between pro- and anti-angiogenic factors. It was 
demonstrated that the critical step in establishing the angio-
genic capability of human cells is the repression of the criti-
cal anti-angiogenic factor, thrombospondin-1 (Tsp-1) [263]. 
This repression is essential for tumor formation by mammary 
epithelial cells and kidney cells engineered to express SV40 
early region proteins, hTERT, and H-RasV12. It was demon-
strated that Ras induces the sequential activation of PI3K, 
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phorylation [263]. Phosphorylation of Myc via this mecha-
nism enables it to repress Tsp-1 expression [263]. Thus a 
novel mechanism by which the cooperative activity of the 
oncogenes, Ras and Myc, leads directly to angiogenesis and 
tumor formation was described [263]. 
  Over-expression of the v-P3k protein or of cellular PI3K 
equipped with a myristylation signal, Myr-P3k, induced an-
giogenesis in the chorioallantoic membrane (CAM) of the 
chicken embryo [264]. Over-expression of the myristylated 
form of the PI3K Akt (Myr-Akt) also induces angiogenesis 
[264]. Over-expression of the tumor suppressor PTEN or of 
dominant-negative constructs of PI3K inhibited angiogenesis 
in the yolk sac of chicken embryos, suggesting that PI3K and 
Akt signaling is required for normal embryonal angiogene-
sis. The levels of mRNA for VEGF were elevated in cells 
expressing activated PI3K or Myr-Akt [264]. In human pros-
tate cancer cells, basal-, growth factor-, and mitogen-induced 
expression of HIF-1, was blocked by LY294002 and ra-
pamycin [255]. HIF-1-dependent gene transcription was 
blocked by dominant-negative Akt or PI3K and by wild-type 
PTEN, whereas transcription was stimulated by constitu-
tively active Akt or dominant-negative PTEN [255]. These 
data indicated that pharmacological agents that target PI3K, 
Akt, or mTOR/FRAP in tumor cells inhibit HIF-1 expres-
sion and that such inhibition may contribute to therapeutic 
efficacy. In glioblastoma cells, transcriptional regulation of 
the VEGF promoter by EGFR was reported to involve 
Ras/PI3K but to be distinct from signals induced by hypoxia 
[265]. In breast cancer cell lines LY294002 inhibited HIF-1 
induction and phosphorylation under hypoxia [266]. Basal 
and hypoxia-inducible VEGF expression was reduced at 
both mRNA and protein levels [266]. V12-Ras overexpres-
sion resulted in an increase in hypoxia-induced HIF-1, 
which was blocked by the PI3K inhibitor, demonstrating one 
mechanism for Ras synergy with hypoxia-mediated induc-
tion of genes [266]. The decreased HIF-1 expression was 
not dependent on VHL interaction [266]. Results from an-
other study indicated that HER2 can induce HIF activation 
via the activation of Akt suggesting that activation of 
HER2/Akt pathway may promote angiogenesis independent 
of hypoxia, which may have important implications for the 
oncogenic activity of HER2 and Akt [267]. 
  To genetically test the relationship between HIF-1 and 
Akt, activated Akt was expressed in a hepatoma cell line 
lacking HIF-1 [268]. Akt expression was associated with a 
dramatic increase in tumor size, despite the absence of HIF-1 
[268]. Tumor size was not further increased in cells with 
reconstituted HIF-1 activity, indicating that the effects of 
Akt on tumorigenesis were not limited by the absence of 
HIF-1 [268]. Increased tumor size in Akt-expressing, HIF-
deficient cells was associated with VEGF secretion and tu-
mor vascularization. Thus, Akt also has potent, HIF-1-
independent oncogenic and angiogenic activities [268]. 
  Another study used the Cre-loxP system to generate an 
endothelial cell-specific mutation of PTEN in mice [269]. 
The gene-targeted mice displayed enhanced tumorigenesis 
due to an increase in angiogenesis driven by vascular growth 
factors, an effect which was partially dependent on the p85 
and p110 PI3K isoforms [269]. A critical role for PTEN/ 
PI3K in tumor angiogenesis was thus confirmed [269]. 
PI3K SIGNALING IN AUTOPHAGY 
  Autophagy is a vacuolar, self-digesting mechanism re-
sponsible for the removal of long-lived proteins and dam-
aged organelles by the lysosome [270, 271]. The discovery 
of the autophagy (Atg) genes has provided key information 
about the formation of the autophagosome, and about the 
role of macroautophagy in allowing cells to survive during 
nutrient depletion and/or in the absence of growth factors 
[270, 271]. Two connected signaling pathways encompass-
ing class I PI3K and mTOR play a central role in controlling 
macroautophagy in response to starvation [271]. However, a 
considerable body of literature reports that macroautophagy 
is also a cell death mechanism that can occur either in the 
absence of detectable signs of apoptosis (via autophagic cell 
death) or concomitantly with apoptosis [271]. Macroauto-
phagy is activated by signaling pathways that also control 
apoptosis [271]. 
  It was shown that rapamycin induced autophagy but not 
apoptosis in rapamycin-sensitive malignant glioma cells by 
inhibiting the function of mTOR [272]. In contrast, in ra-
pamycin-resistant glioma cells, the inhibitory effect of ra-
pamycin was minor, although the phosphorylation of 
p70(S6K) was inhibited [272]. Interestingly, LY294002 or 
an Akt inhibitor both synergistically sensitized rapamycin-
sensitive and insensitive cells to rapamycin by stimulating 
the induction of autophagy [272]. 
  Multiple class III PI3K Vps34p-Vps15p complexes asso-
ciated with specific regulatory proteins were described and 
shown to be involved in membrane trafficking events at dif-
ferent sites, with functions in autophagy and carboxypepti-
dase Y (CPY) sorting [273]. Beclin is involved in the proc-
ess of autophagy. It was shown that Beclin was co-
immunoprecipitated with Vps34p, which is also required for 
autophagy [274], suggesting that Beclin is a component of 
the Vps34p complex [275]. Vps34p was shown to regulates 
carboxypeptidase Y sorting, the constitutive autophagy in-
volving the cytoplasm-to-vacuole targeting (Cvt) and mac-
roautophagy pathways through distinct sets of PI(3)P-
binding effectors and that Vps34p promotes protein traffick-
ing in the Cvt pathway through activation/localization of the 
effector protein Etf1 [276]. 
THE ONCOGENIC POTENTIAL OF PI3K 
  The oncogenic potential of PI3K was first described by 
studies on ASV 16, a retrovirus that induces hemangiosar-
comas in chickens. Analysis of the ASV 16 genome revealed 
that it encodes an oncogene that is derived from the cellular 
gene for the catalytic subunit of PI3K. The gene is referred 
to as v-p3k, and like its cellular counterpart c-p3k, it is a 
potent transforming gene in cultured chicken embryo fibro-
blasts (CEFs) [277]. Certain mutated forms of Akt induced 
oncogenic transformation in chicken embryo fibroblast cul-
tures and hemangiosarcomas in young chickens [278]. This 
ability to transform cells depends on localization of Akt at 
the plasma membrane and on the kinase activity of Akt 
[278]. A transdominant negative form of Akt interfered with 
oncogenic transformation induced by the p3k oncogene 
[278]. Akt was therefore shown to be an essential mediator 
of p3k-induced oncogenicity [278]. The transformed cells 
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eukaryotic initiation factor 4E-BP1 binding protein (4E-BP1) 
[279]. Rapamycin effectively blocked oncogenic transforma-
tion induced by either p3k or Akt, in accord with the hy-
pothesis that transformation by p3k or Akt involves mTOR 
and intervention in translational controls [279]. 
  The ability of activated Ras to stimulate PI3K in addition 
to Raf was important in Ras transformation of mammalian 
cells and essential in Ras-induced cytoskeletal reorganization 
[280]. Further studies showed that PI3K promotes anchor-
age-independent cell growth, entry into the cell cycle and 
that prolonged PI3K activation resulted in cellular changes 
that resemble those associated with oncogenic transforma-
tion [281]. Ras oncogene activation induces a proliferative 
phenotype in normal human thyroid epithelial cells in vitro, 
consistent with its putative role in tumor initiation [282]. In 
this model, it was shown that PI3K is an absolute require-
ment for the proliferative response to Ras in these cells, act-
ing via suppression of Ras-induced apoptosis [283]. IRS-1, 
but not Shc, in combination with v-Ha-Ras generates a fully 
transformed phenotype in 32D cells [284]. Furthermore, 
transformed 32D/IRS1/Ras cells displayed high levels of 
PI3K activation and underwent rapid apoptosis when ex-
posed to PI3K inhibitors [284]. Another study described an 
important role for PI3K/Akt in Ras-mediated transformation 
of intestinal epithelial cells [285]. Carcinogenesis by onco-
genic Ras and Her-2 involves enhanced proliferation of 
epithelial cells in vivo. It was demonstrated that oncogenic 
H-Ras or constitutively active Her-2 cause increased prolif-
eration and cyclin D1 upregulation in fully polarized, mam-
mary epithelial cells (EpH4), if cultivated as organotypic 
structures in three-dimensional collagen/matrigel matrices 
[286]. It was shown that the Ras-activated PI3K pathway is 
required to induce rapid tumor growth and enhanced prolif-
eration of EpH4 cells in collagen gels, but fails to cause 
EMT  in vitro and in vivo [286]. Another report suggested 
that Ras may only affect PI3K signaling when mutationally 
activated, such as in Ras(V12)-transformed cells, providing a 
basis for understanding the synergy between Ras and other 
growth-promoting oncogenes in cancer [287]. In human 
mammary epithelial cells (HMECs) expressing elevated c-
Myc, activated H-Ras is dispensable for anchorage-indepen- 
dent growth. Using this system, it was shown that SV40 
small t antigen (st) activates the PI3K pathway and that con-
stitutive PI3K signaling substitutes for st in transformation 
[288]. Moreover, using constitutively active versions of Akt1 
and Rac1, it was shown that these downstream pathways of 
PI3K synergize to achieve anchorage-independent growth 
[288]. At lower levels of c-Myc expression, activated PI3K 
also replaces st to complement H-RasV12 and SV40 large T 
antigen (LT) and confers both soft agar growth and tumori-
genicity [288]. These observations defined the pathways 
perturbed during the transformation of HMECs [288]. 
  PI3K and some of its downstream targets, such as Akt 
and p70(S6K) are crucial effectors in oncogenic protein-
tyrosine kinase signaling [289]. The ability of the BCR-ABL 
tyrosine kinase fusion protein to transform hematopoietic 
cells required PI3K/Akt [290, 291]. BCR/ABL suppresses 
p27(Kip1) protein levels through PI3K/Akt, leading to accel-
erated entry into S phase [292]. This activity is likely to ex-
plain in part previous studies showing that activation of 
PI3K was required for optimum transformation of hema-
topoietic cells by BCR/ABL in vitro and in vivo [292]. It was 
also shown that inhibition of p27(Kip1) transcription through 
PI3K/Akt involves phosphorylation of the forkhead tran-
scription factor FKHR-L1 [293]. In addition, an ubiquitin E3 
ligase, the SCF(SKP2) complex, mediates p27(Kip1) ubiq-
uitin-dependent proteolysis. It was shown that SKP2 func-
tions as a critical component in the PTEN/PI3K pathway for 
the regulation of p27(Kip1) and cell proliferation [294]. 
BCR-ABL was shown to regulate the cell cycle in CML cells 
at least in part by inducing proteasome-mediated degradation 
of the cell cycle inhibitor p27(Kip1), which depends on 
SKP2 [295]. Further work showed that activation of class IA 
PI3K and downstream inactivation of FOXO transcription 
factors are essential for survival of murine pro/pre-B cells 
transformed by v-ABL or BCR-ABL [296]. In addition, 
analysis of mice lacking individual PI3K genes indicates that 
products of the PIK3R1 gene contribute to transformation 
efficiency by BCR-ABL [296]. These findings established a 
role for PI3K signaling in B-lineage transformation by ABL 
oncogenes. 
  The most frequently found alteration of the epidermal 
growth factor receptor (EGFR) in human tumors is a deletion 
of exons 2-7. This receptor is termed EGFRvIII. High levels 
of PI3K activity were constitutively present in EGFRvIII-
transformed cells and were dependent upon the kinase activ-
ity of the receptor. Treatment with the PI3K inhibitors wort-
mannin and LY294002 blocked both anchorage-independent 
growth and growth in low serum media and also resulted in 
morphological reversion of EGFRvIII-transformed cells 
[47]. Results from another study suggested that the constitu-
tively active EGFRvIII can enhance cell proliferation in 
glioblastoma in part by down-regulation of p27(Kip1) 
through activation of the PI3K/Akt pathway [297]. ErbB-2-
overexpressing human mammary epithelial (HME) cells ex-
hibit several transformed phenotypes including growth factor 
independence, anchorage-independent growth, motility, and 
invasiveness [298]. To identify pathways leading from PI3K 
to specific phenotypes, constitutively active Akt or PTEN 
were expressed in erbB-2-overexpressing cells, or in HME 
cells [298]. HME cells expressing constitutively active Akt 
were growth factor-independent, anchorage-independent and 
motile, but not invasive [298]. PTEN expression blocked 
erbB-2-mediated invasion but none of the other phenotypes 
[298]. This study concluded that a PI3K-dependent and 
p38MAPK-dependent pathways lead to activation of Akt, 
and activation of PKC, via PI3K, mediates invasion [298]. 
Breast cancer cells over-expressing ErbB2 depend on its 
activity for proliferation, because treatment of these cells 
with ErbB2-specific antagonistic antibodies or kinase inhibi-
tors blocks tumor cells in the G1 phase of the cell cycle. 
ErbB3 is a partner for ErbB2 in promoting cellular transfor-
mation [299]. Loss of functional ErbB2 or ErbB3 had similar 
effects on cell proliferation and cell cycle regulators [299]. 
Furthermore, expression of constitutively active Akt rescued 
the proliferative block induced as a consequence of loss of 
ErbB2 or ErbB3 signaling [299]. These results demonstrated 
that ErbB2 over-expression and activity alone are insuffi-
cient to promote breast tumor cell division. ErbB3's role is to 
couple active ErbB2 to the PI3K/Akt pathway [299]. Thus, 
the ErbB2/ErbB3 dimer functions as an oncogenic unit to 
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  Polyomavirus (PyV) middle T antigen (MT)-mediated 
tumorigenesis required activation of both Shc and PI3K, 
which appeared to be required for stimulation of cell prolif-
eration and survival signaling pathways, respectively [300, 
301]. In mammary epithelium, it was reported that activation 
of Akt can contribute to tumor progression by providing an 
important cell survival signal but does not promote metas-
tatic progression [302]. Transgenic mice expressing constitu-
tively active Akt were generated. Although expression of 
activated Akt interfered with normal mammary gland involu-
tion, tumors were not observed in these strains [302]. How-
ever, coexpression of activated Akt with a mutant middle T 
antigen decoupled from PI3K (MTY315/322F) resulted in a 
dramatic acceleration of mammary tumorigenesis correlated 
with reduced apoptotic cell death [302]. Furthermore, co-
expression of activated Akt with MTY315/322F resulted in 
phosphorylation of the FKHR transcription factor and trans-
lational up-regulation of cyclin D1 levels [302]. 
  Transformation of chicken embryo fibroblasts (CEF) by 
v-Src was mediated by two parallel pathways, the Ras-
MAPK pathway and the PI3K-mTOR pathway, which both 
contributed to transformation [303]. v-Src induced constitu-
tive activation of phosphatidylinositol 3-kinase led to factor-
independent proliferation [304]. A dominant-negative mutant 
of PI3K (Deltap85) partially inhibited v-Src-dependent 
growth [304]. MEN2A and FMTC mutations result in a con-
stitutive catalytic activity of the RTK RET and as a conse-
quence convert RET into a dominantly acting transforming 
gene. The mutant RET-mediated cell-transforming effect 
was shown to be critically dependent on the activation of the 
PI3K/AKT pathway [305]. Membrane localization of the the 
constitutively activated Tpr-Met oncoprotein enhanced cellu-
lar transformation, focus formation, and anchorage-indepen- 
dent growth and induces tumors with a distinct myxoid phe-
notype [306]. This correlated with the induction of hyaluro- 
nic acid (HA) and the presence of a distinct form of its re-
ceptor, CD44 [306]. A pharmacological inhibitor of PI3K 
inhibited the production of HA, and conversely, an activated, 
plasma membrane-targeted form of PI3K was sufficient to 
enhance HA production [306]. These results provided a posi-
tive link to a role for HA and CD44 in Met receptor-
mediated oncogenesis and implicated PI3K in these events 
[306]. v-Crk induces cellular tyrosine phosphorylation and 
transformation of chicken embryo fibroblasts (CEF). Consti-
tutive activation of the PI3K/Akt pathway by v-Crk was 
shown to play an essential role in v-Crk-induced transforma-
tion of CEF [307]. A subsequent report suggested the in-
volvement of the PI3K/Akt survival pathway in the v-Crk-
induced protection against apoptosis [308]. NPM/ALK en-
codes a constitutively activated tyrosine kinase that belongs 
to the family of tyrosine kinases activated by the chromoso-
mal translocation t(2;5) in a subset of anaplastic large cell 
lymphomas. It was reported that NPM/ALK constitutively 
activates the PI3K-Akt pathway and that this pathway plays 
an important role in the NPM/ALK-mediated malignant 
transformation [309]. Studies with a PI3K inhibitor and a c-
Kit mutant incapable of recruiting PI3K, indicated that con-
stitutive activation of PI3K through direct recruitment by 
constitutively active D816V c-Kit plays a role in factor-
independent growth of immortalized murine progenitor cells 
and is critical for tumorigenicity [310]. 
  To determine the specific functions of p110, mice car-
rying a conditionally targeted allele of the PIK3CA gene 
were generated [311]. PIK3CA-knockout mouse embryonic 
fibroblasts were deficient in cellular signaling in response to 
various growth factors and resistant to oncogenic transfor-
mation induced by a variety of oncogenic receptor tyrosine 
kinases, indicating a fundamental role for p110 in these 
biological processes [311]. In a recent study, mice with mu-
tations in the PIK3CA gene that block its interaction with 
Ras were generated [312]. Cells from these mice showed 
proliferative defects and selective disruption of signaling 
from growth factors to PI3K. Importantly, the mutant mice 
were highly resistant Ras oncogene-induced tumorigenesis 
[312]. The interaction of Ras with p110 was thus demon-
strated to be required in vivo for normal growth factor signal-
ing and for Ras-driven tumor formation [312]. 
ALTERATIONS IN PI3K SIGNALING IN CANCER 
  A summary of the main genetic alterations described in 
the PI3K signaling pathway is presented in Table 1. We will 
first discuss the evidence describing altered PI3K signaling 
in human cancer, before more specifically addressing altera-
tions in PTEN, PIK3CA and the p85 regulatory subunit of 
PI3K. 
ACTIVATION OF THE PI3K/Akt SIGNALING 
PATHWAY IN HUMAN CANCER 
  A first study showed that colorectal tumors exhibited 
enhanced PI3K activity compared with normal colonic mu-
cosa, raising the possibility that PI3K may be a potential 
target for new strategies for the treatment of colorectal carci-
noma [313]. In small cell lung cancer (SCLC) initial reports 
found high basal constitutive PI3K activity, which results in 
high basal Akt and ribosomal p70(S6K) activity [314]. Inhi-
bition of PI3K activity markedly inhibited SCLC cell prolif-
eration in liquid culture as a result of stimulating apoptosis 
and promoting cell cycle delay in G1 [314]. Thus, constitu-
tive PI3K activity in SCLC cells was proposed to play an 
important role in promoting the growth and anchorage inde-
pendence of SCLC [314]. Another study identified Akt as a 
constitutively active kinase that promotes survival of 
NSCLC cells and demonstrated that modulation of Akt activ-
ity by pharmacological or genetic approaches alters the cel-
lular responsiveness to therapeutic modalities such as che-
motherapy or radiotherapy [315]. Elevated phospho-Akt 
staining was reported in 65% human malignant mesothelio-
mas (MM) specimens [316]. In addition, Akt phosphoryla-
tion was consistently observed in MMs arising in asbestos-
treated mice and in MM cell xenografts [316]. Treatment of 
a MM cell line with rapamycin resulted in growth arrest in 
G1 phase, while LY294002 in combination with cisplatin 
had greater efficacy in inhibiting cell proliferation and induc-
ing apoptosis than either agent alone [316].  
  A report showed activation of Akt2 in human primary 
ovarian cancer and induction of apoptosis by inhibition of 
PI3K/Akt pathway [317]. The majority of tumors displaying 
activated Akt2 were high grade and stages III and IV [317]. 
Immunostaining and Western blot analyses using a phospho-
Ser-473 Akt antibody that detects the activated form of Akt2 
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specimens [317]. Another study determined the frequency of 
Akt activation in ovarian cancer and found elevated staining 
(phosphor-Ser473) in 68% ovarian carcinomas [318]. In an-
other report, significantly increased Akt1 kinase activity was 
detected in primary carcinomas of prostate, breast, and ovary 
[319]. The majority of Akt1-activated tumors were high 
grade and stage III/lV [319].  
  In thyroid cancer, increased levels of phosphorylated 
total Akt were identified in follicular but not papillary can-
cers compared with normal tissue [320]. Levels of Akt1 and 
Akt2 proteins and Akt2 RNA were elevated only in the fol-
licular cancers [320]. In paired samples, Akt 1, 2, 3, and 
phospho-Akt levels were higher in cancers [320]. These data 
suggested that Akt activation may play a role in the patho-
genesis or progression of sporadic thyroid cancer [320]. In 
head and neck cancer, a significant association was found 
between phospho-Akt staining and local recurrence in the 
patient series. Evaluation of PI3K activation by Akt phos-
phorylation was thus suggested to be a prognostic marker for 
response to therapy [321]. Immunohistochemical analyses in 
breast carcinomas revealed that elevated expression of HER-
2/neu was found to correlate with over-expression of Akt2 
protein and activation of Akt kinase [322]. HER-2/neu-
overexpressing breast cancer cell lines were resistant to 
apoptosis induced by UV treatment and hypoxia, which was 
suppressed in the presence of the PI3K inhibitors LY294002 
and wortmannin, indicating a link between Akt activation 
and stress resistance in HER-2/neu-overexpressing cells 
[322]. In colorectal carcinomas, immunohistochemical 
analysis showed that 46% of the tumors had a high level of 
expression of phosphorylated Akt with a close association 
with Ki-67 proliferative activity and the number of apoptotic 
bodies [323]. Akt phosphorylation was also correlated with 
clinicopathologic parameters of the malignancies, including 
depth of invasion, infiltration to venous vessels, lymph node 
metastasis, and clinicopathologic stage [323]. It was con-
cluded that activation of Akt plays an important role during 
the progression of colorectal carcinomas by helping promote 
cell growth and rescue cells from apoptosis [323].  
  Another study suggested that PI3K has a major role in 
the control of proliferation and apoptosis of growth factor-
independent multiple myeloma cell lines [324]. Constitutive 
activation of this pathway was shown to be a frequent event 
in the biology of multiple myeloma in vivo and may be more 
frequently observed in primary plasma cell leukemia [324]. 
Purified plasmocytes from patients with myeloma or leuke-
mia displayed constitutive phosphorylation of Akt, FKHRL-
1 and p70(S6K), which was inhibited by LY294002 and en-
hanced by IGF-I [324]. Another study demonstrated that Akt 
is activated in AML blasts and that p70(S6K) and 4EBP-1, 
downstream mediators of Akt signaling, also are phosphory-
lated in AML blasts [325]. In a short-term culture system, 
most AML patient samples showed a dose-dependent de-
crease in survival after incubation with LY294002 [325]. 
Incubation of AML blasts with RAD001 induced only a 
small decrease in survival of the cells [325]. However, when 
combined with Ara-C, RAD001 enhanced the toxicity of 
Ara-C [325]. These results demonstrated that constitutive 
activation of the PI3K pathway is necessary for the survival 
of AML blasts and that targeting of this pathway with phar-
Table 1.  Genetic Alterations in the PI3K/Akt Pathway in Cancer 
Pathway 
Component 
Type of Alteration  Tumor Lineage  References 
Loss-of-function by somatic mutation  Brain, prostate, endometrium  [479-481] 
Germline mutation (in 80% of Cowden Disease) 
Cowden disease: Increased risk for breast, thyroid, genitou-
rinary and endometrial cancer 
[482, 483] 
Transcriptional down-regulation  
(e.g., promoter methylation) 
Melanoma, breast, colon  [484-486] 
PTEN 
Loss of heterozygosity 
Prostate, melanoma, thyroid, breast, pancreas, ovary, brain, 
bladder, endometrium, cervix, head and neck, kidney, lung 
Reviewed in [487] 
Gain-of-function by somatic mutation  Colon, breast, brain, ovary  [387, 390] 
p110 
Amplification  Ovary, gastric, lung, cervix  [382, 391, 488, 489] 
p85  Gain-of-function by somatic mutation  Brain, colon, ovary  [413, 490] 
AKT1  Gain-of-function by somatic mutation  Breast, colorectal, ovary  [491] 
Amplification  Ovary, lymphoma, pancreas  [492-495] 
AKT2 
Mutation Colorectal  [389] 
PDK1  Mutation Colorectal  [389] 
TSC 1/2 
Loss-of-function by mutation (occasionally with  
concomitant loss of heterozygosity for the wild type allele) 
Tuberous sclerosis (hamartomas of the skin, brain and 
kidney; rare progression to malignancy) 
[224] 
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macologic inhibitors may be of clinical benefit in treatment 
of AML [325]. Another study demonstrated that the overall 
survival of patients with the Akt phosphoryated on Ser473 
was significantly shorter than that of patients without [326]. 
Thus, the detection of the Akt phosphorylation may provide 
a new tool for identifying AML patients at high risk of an 
unfavorable outcome [326]. 
  Based on the observation that melanoma cell lines exhibit 
constitutive Akt activation, this event was evaluated by im-
munohistochemistry [327]. Normal and slightly dysplastic 
nevi exhibited no significant Akt expression, in marked con-
trast to the dramatic Akt immunoreactivity seen in severely 
dysplastic nevi and melanomas [327]. It was proposed that 
activation of Akt may be an early marker for tumor progres-
sion in melanoma [327]. 
  In glioma, a study analysed the levels of expression of 
PI3K pathway members through quantitative Western analy-
sis [328]. Levels of phospho-Akt, and phospho-p70(S6K) 
were all found to be inversely associated with cleaved 
caspase-3 levels, suggesting PI3K pathway activation is as-
sociated with reduced levels of apoptosis [328]. Activation 
of PI3K pathway members was found to be significantly 
associated with reduced survival times [328].  
  A study examined the status of activation of Akt in dif-
ferent stages of squamous cell carcinoma development in 
clinical samples from squamous carcinomas of the head and 
neck (HNSCC) patients [329]. By immunohistochemical 
analysis, it was demonstrated that activation of Akt is a fre-
quent event in human HNSCC because active Akt could be 
detected in these tumors with a pattern of expression and 
localization correlating with the progression of the lesions 
[329]. In line with these observations, Akt was constitutively 
activated in a large fraction of HNSCC-derived cell lines 
[329]. 
  Gefitinib, a specific epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor, was shown to have activity 
against approximately 10% of unselected non-small-cell lung 
cancer (NSCLC) patients. An important finding was that 
patients with phosphorylated Akt-positive tumors who re-
ceived gefitinib had a better response rate, disease control 
rate, and time to progression than patients with phosphory-
lated Akt-negative tumors, suggesting that gefitinib may be 
most effective in patients with basal Akt activation [330]. 
THE TUMOR SUPPRESSOR PTEN 
Discovery of PTEN as an Antagonist of the PI3K/Akt 
Pathway 
  The tumor suppressor called phosphatase and tensin ho-
molog deleted on chromosome 10 (PTEN) (or MMAC1) is 
located on human chromosome 10q23, and was initially de-
scribed as sharing homology with the protein tyrosine phos-
phatase family [331, 332]. Germline mutations in PTEN give 
rise to several related neoplastic disorders, including Cow-
den disease [331, 333, 334]. It was demonstrated that over-
expression of PTEN reduced insulin-induced PIP3 produc-
tion in human cells without effecting insulin-induced PI3K 
[335]. Purified recombinant PTEN catalyzed dephosphoryla-
tion of PIP3, specifically at position 3 on the inositol ring 
[335]. These results established the function of PTEN as a 
phosphoinositide 3-phosphatase by regulating PIP3 levels 
[335]. Although more than half of PTEN mutations result in 
protein truncation, a significant fraction of PTEN mutations 
are missense mutations. It was shown that the majority of 
PTEN missense mutations (90%) eliminated or reduced 
phosphatase activity towards inositol 1,3,4,5-tetrakisphos- 
phate and PIP3 [336]. It was reported that a missense muta-
tion in PTEN, PTEN-G129E, which is observed in two 
Cowden disease kindreds, specifically ablates the ability of 
PTEN to recognize inositol phospholipids as a substrate, 
suggesting that loss of the lipid phosphatase activity is re-
sponsible for the etiology of the disease [337]. Furthermore, 
expression of wild-type or substrate-trapping forms of PTEN 
in mammalian cells altered the levels of the phospholipid 
products of PI3K and ectopic expression of the phosphatase 
in PTEN-deficient tumor cell lines resulted in the inhibition 
of PKB/Akt and regulation of cell survival [337]. It was also 
shown that glioblastoma cells, in contrast to primary human 
astrocytes, contain high endogenous Akt activity and high 
levels of PI(3,4,5)P3 and PI(3,4)P2, the lipid products of 
PI3K [338]. These glioblastoma cells were shown to express 
mutant forms of PTEN [338]. PTEN antagonized the activa-
tion of PKB/Akt by growth factors, by activated PI3K and 
by PDK1, but did not antagonize the phospholipid-indepen-
dent activation of PKB/Akt lacking the PH domain [338]. 
These results confirmed a role for PTEN in regulating the 
activity of the PI3K pathway in malignant human cells. An-
other study demonstrated that the acute administration of 
MMAC/PTEN in glioma cells infected with recombinant 
adenoviruses resulted in the inhibition of Akt-mediated sig-
naling, growth inhibition, and anoikis [339]. In another re-
port, PTEN inhibited cell growth and/or colony formation in 
epithelial cell lines [340]. The decrease in cellular prolifera-
tion was associated with an induction of apoptosis and an 
inhibition of signaling through the PI3K pathway [340]. Akt/ 
PKB was able to rescue cells from PTEN-dependent death 
[340]. PTEN expression potently suppressed the growth and 
tumorigenicity of human glioblastoma U87MG cells [341]. 
The growth suppression activity of PTEN was mediated by 
its ability to block cell cycle progression in the G1 phase 
[341]. Such an arrest correlated with a significant increase of 
the cell cycle kinase inhibitor p27(KIP1) and a concomitant 
decrease in the activities of the G1 cyclin-dependent kinases 
[341]. PTEN expression also led to the inhibition of Akt/ 
PKB [341]. Further work implicated p27(KIP1) as a critical 
mediator of PTEN-induced G1 arrest [342]. It was also 
shown that PTEN protein induces a G1 block when reconsti-
tuted in PTEN-null cells [343]. A PTEN mutant associated 
with Cowden's disease (PTEN;G129E) has protein phospha-
tase activity yet is defective in dephosphorylating inositol 
1,3,4,5-tetrakisphosphate in vitro and fails to arrest cells in 
G1 [343]. These data suggest a link between induction of a 
cell-cycle block by PTEN and its ability to dephosphorylate, 
in vivo, PIP3 [343]. In a parallel study, PTEN impaired acti-
vation of endogenous Akt in cells and inhibited phosphoryla-
tion of 4E-BP1 [344]. In addition, PTEN/ MMAC1 repressed 
gene expression in a manner that is rescued by Akt but not 
PI3K [344]. Finally, higher levels of Akt activation are ob-
served in human prostate cancer cell lines and xenografts 
lacking PTEN/MMAC1 expression when compared with 
PTEN/MMAC1-positive prostate tumors or normal prostate 
tissue [344].  The Phosphoinositide 3-Kinase Pathway in Human Cancer  Current Genomics, 2007, Vol. 8, No. 5    283 
Animal Models 
  PTEN-mutant mouse embryos displayed regions of in-
creased proliferation [345]. In contrast, PTEN-deficient im-
mortalized mouse embryonic fibroblasts exhibited decreased 
sensitivity to cell death in response to a number of apoptotic 
stimuli, accompanied by constitutively elevated activity and 
phosphorylation of PKB/Akt [345]. Expression of exogenous 
PTEN in mutant cells restores both their sensitivity to ago-
nist-induced apoptosis and normal pattern of PKB/Akt phos-
phorylation. Furthermore, PTEN negatively regulated intra-
cellular levels of PIP3 in cells and dephosphorylates it in 
vitro [345]. These results showed that PTEN may exert its 
role as a tumor suppressor by negatively regulating the 
PI3K/PKB/Akt signaling pathway. The PTEN  gene was 
shown to be fundamental for embryonic development in 
mice, as PTEN mutant embryos died by day 9.5 of gestation 
[346]. Heterozygous mice developed lymphomas associated 
with loss of heterozygosity of the wild-type PTEN allele, and 
tumor appearance was accelerated by gamma-irradiation 
[346]. These lymphomas had high levels of activated 
Akt/PKB [346]. This suggested that tumors associated with 
PTEN loss of heterozygosity may arise as a consequence of 
an acquired survival advantage [346]. When more than 6 
months old, PTEN(+/-) mice were shown to develop a range 
of tumors, partially resembling the spectrum of neoplasia 
observed in Cowden's syndrome patients [347]. One-half of 
PTEN (+/-) females developed breast tumors, whereas all of 
the females had endometrial hyperplasia, and there was a 
high incidence of endometrial cancer [347]. Analysis of 
prostate cancer progression in transgenic adenocarcinoma of 
mouse prostate mice bred to PTEN(+/-) heterozygous mice, 
coupled with analysis of the PTEN gene and protein in the 
resulting tumors, revealed that haploinsufficiency of the 
PTEN gene promotes the progression of prostate cancer in 
this model system [348]. Using the Cre-loxP system, another 
group selectively inactivated PTEN in skin and prostate in 
mice [349]. Abnormalities in PTEN mutant skin consisted of 
mild epidermal hyperplasia, whereas prostates from these 
mice exhibited high-grade prostatic intraepithelial neoplasia 
that frequently progressed to focally invasive cancer [349]. 
These data demonstrated that PTEN is an important physio-
logical regulator of growth in the skin and prostate [349]. 
Further, the early onset of prostatic neoplasia in PTEN mu-
tant males implicated PTEN mutations in the initiation of 
prostate cancer. Consistent with high PTEN mutation rates in 
human prostate tumors, these data indicated that PTEN is a 
critical tumor suppressor in this organ. 
  Primordial germ cells (PGCs), which are the embryonic 
precursors of gametes, are the source of testicular teratoma. 
To elucidate the intracellular signaling mechanisms that un-
derlie germ cell differentiation and proliferation, mice with a 
PGC-specific deletion of the PTEN gene were generated 
[350]. Male mice that lacked PTEN exhibited bilateral tes-
ticular teratoma, which resulted from impaired mitotic arrest 
and outgrowth of cells with immature characters [350]. Ex-
periments with PTEN-null PGCs in culture revealed that 
these cells had greater proliferative capacity and enhanced 
pluripotent embryonic germ cell colony formation [350]. 
PTEN thus appears to be essential for germ cell differentia-
tion and an important factor in testicular germ cell tumor 
formation [350].  
  In another study aimed at determining the role of the 
PI3K pathway in pancreas development, a pancreas-specific 
knockout of PTEN was generated [351]. Knockout mice dis-
played progressive replacement of the acinar pancreas with 
highly proliferative ductal structures that contained abundant 
mucins and expressed markers of pancreatic progenitor cells 
[351]. Moreover, a fraction of these mice develop ductal 
malignancy [351]. Thus, misregulation of the PI3K pathway 
may contribute to the initiation of pancreatic carcinoma in 
vivo [351]. 
Functional Consequences of PTEN Inactivation 
  A null mutation was introduced into the mouse PTEN 
gene by homologous recombination in embryonic stem (ES) 
cells [352]. PTEN (-/-) ES cells exhibited an increased 
growth rate and proliferated even in the absence of serum. 
ES cells lacking PTEN function also displayed advanced 
entry into S phase [352]. This accelerated G1/S transition 
was accompanied by down-regulation of p27(KIP1), a major 
inhibitor for G1 cyclin-dependent kinases [352]. Inactivation 
of PTEN in ES cells and in embryonic fibroblasts resulted in 
elevated levels of PIP3. Consequently, PTEN deficiency led 
to dosage-dependent increases in phosphorylation and acti-
vation of Akt/PKB and Akt activation increased Bad phos-
phorylation and promoted PTEN (-/-) cell survival [352]. 
Fas-mediated apoptosis was impaired in PTEN (+/-) mice, 
and T lymphocytes from these mice show reduced activa-
tion-induced cell death and increased proliferation upon acti-
vation. PI3K inhibitors restored Fas responsiveness in PTEN 
(+/-) cells [353]. These results indicated that PTEN is an 
essential mediator of the Fas response and a repressor of 
autoimmunity and thus implicated PI3K/Akt pathway in Fas-
mediated apoptosis [353]. 
  PTEN was shown to suppress breast cancer growth 
through down-regulating PI3K signaling, which leads to the 
blockage of cell cycle progression and the induction of cell 
death in a sequential manner [354]. In breast cancer cells 
under anchorage-independent conditions, PTEN also induced 
anoikis, a form of apoptosis that occurs when cells are disso-
ciated from the extracellular matrix, which is enhanced in 
conjunction with low serum culture conditions [355]. To-
gether, these data suggest that PTEN effects on the PI3K 
signaling cascade are influenced by the cell stimulatory con-
text, and that depending on the exposure to growth factors 
and other exogenous stimuli such as integrin ligation, PTEN 
can induce cell cycle arrest, apoptosis or anoikis in breast 
cancer cells. The tumour suppressor activities of PTEN were 
linked to the machinery controlling cell cycle through the 
modulation of signaling molecules whose final target is the 
functional inactivation of the retinoblastoma gene product 
[356]. Expression of wild-type PTEN reduced the expression 
of cyclin D1 [357]. Cyclin D1 reduction was accompanied 
by a marked decrease in endogenous retinoblastoma (Rb) 
protein phosphorylation on cyclin D/CDK4-specific sites, 
showing an early negative effect of PTEN on Rb inactiva-
tion. PTEN expression also prevented cyclin D1 from local-
izing to the nucleus during the G(1)- to S-phase cell cycle 
transition [357]. The PTEN-induced localization defect and 
the cell growth arrest could be rescued by the expression of a 
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an important effect of PTEN is at the level of nuclear avail-
ability of cyclin D1 [357]. Furthermore, in human glioblas-
toma cells, PTEN mutation can cooperate with EGFR activa-
tion to increase VEGF mRNA levels by transcriptionally up-
regulating the proximal VEGF promoter via the PI3K/Akt 
pathway [358]. In addition, the ability of PTEN to potently 
inhibit H-Ras-induced morphological transformation and 
anchorage-independent growth in NIH3T3 cells was reported 
[359]. It was also shown that PTEN can regulate prostate 
cancer cell proliferation and apoptosis through inhibition of 
IGF-IR synthesis [360].  
Clinical Findings 
  Loss of PTEN protein was reported to correlate with 
pathological markers of poor prognosis in prostate cancer 
[361]. A relative reciprocity of mutations in PTEN and NRAS 
was also reported in melanoma, suggesting that the two ge-
netic changes, in a subset of cutaneous melanomas, are func-
tionally overlapping [362]. In multiple myeloma (MM) it 
was shown that human lines possessing the highest Akt ac-
tivity lost PTEN expression [363]. Sequencing analysis 
demonstrated that the PTEN gene contained a deletion. Res-
toration of PTEN expression suppressed IGF-I-induced Akt 
activity, suggesting that loss of PTEN is responsible for un-
controlled Akt activity in MM lines [363]. In lym-
phoma/leukemia-derived cell lines, an inverse relationship 
between PTEN and phosphorylated Akt was observed in 
63% of cell lines [364]. No cell lines showed absence of 
PTEN expression, whereas 50% of cell lines showed low 
PTEN expression [364]. Another study demonstrated the 
phosphorylation of Akt is accompanied by the loss of PTEN 
in clinical specimens of endometrial carcinomas [365]. 
Phosphorylation of Akt was accompanied by the loss of 
PTEN in clinical specimens of endometrial cancers [366]. 
The survival rate for PTEN-positive patients was signifi-
cantly higher than that for PTEN-negative or -heterogeneous 
staining patients, and thus PTEN-positive staining was pro-
posed to be a significant prognostic indicator of favorable 
survival for patients with advanced endometrial cancer 
[366]. In glioma, a strong inverse correlation was described 
between PTEN levels and both phosphorylated Akt expres-
sion and Akt activity [367]. A significant association was 
evident between PTEN expression level and histology. 
PTEN levels were highest in normal brain, lowest in GBM 
tumors, and intermediate in grade II oligoastrocytomas 
[367]. Another study demonstrated that loss PTEN was 
highly correlated with activation of the main PI3K effector 
Akt in vivo [368]. It was also shown that Akt activation is 
significantly correlated with mTOR, the family of forkhead 
transcription factors (FOXO1, FOXO3a, and FOXO4) and 
the S6 protein [368]. Expression of the mutant EGFRvIII 
was also tightly correlated with phosphorylation of these 
effectors, demonstrating an additional route to PI3K pathway 
activation in glioblastomas in vivo [368]. PTEN expression 
correlated significantly with survival time within the entire 
cohort and was associated with survival within the subgroup 
of GBM tumors [367]. Thus, reduced PTEN expression is 
ubiquitous among GBM tumors and may play a role in the 
development of low-grade gliomas. PTEN inactivation in 
gliomas portends a particularly aggressive clinical behavior 
[367]. 
Therapeutic Implications 
  It was shown that transformed cells of PTEN (+/-) mice 
have elevated levels of phosphorylated Akt and activated 
p70(S6K) associated with an increase in proliferation. Phar-
macological inactivation of mTOR/RAFT/FRAP reduced 
neoplastic proliferation, tumor size, and p70(S6K) activity, 
but did not affect the status of Akt [369]. These data sug-
gested that p70(S6K) and possibly other targets of mTOR 
contribute significantly to tumor development and that inhi-
bition of these proteins may be therapeutic for cancer pa-
tients with deranged PI3K signaling [369]. In vitro and in 
vivo studies of isogenic PTEN (+/+) and PTEN (-/-) mouse 
cells as well as human cancer cells with defined PTEN status 
confirmed that the growth of PTEN null cells was blocked 
preferentially by pharmacologic FRAP/mTOR inhibition 
[370]. Enhanced tumor growth caused by constitutive activa-
tion of Akt in PTEN (-/-) cells also was reversed by CCI-779 
(rapamycin derivative) treatment, indicating that mTOR 
functions downstream of Akt in tumorigenesis [370]. Loss of 
PTEN correlated with increased S6 kinase activity and phos-
phorylation of ribosomal S6 protein, providing evidence for 
activation of the FRAP/mTOR pathway in these cells [370]. 
Another study aimed to determine the effects of PTEN status 
and treatment with rapamycin in the response of prostate 
cancer cell lines to doxorubicin [371]. The PTEN-positive 
cells were significantly more susceptible to the anti-
proliferative effects of doxorubicin as compared with the 
PTEN-negative cells. Transfection of PTEN into the PTEN-
negative decreased the activation of Akt and the downstream 
p70(S6K) and reversed the resistance to doxorubicin in these 
cells, indicating that changes in PTEN status/Akt activation 
modulate the cellular response to doxorubicin [371]. Treat-
ment of PC-3 PTEN-negative cells with rapamycin inhibited 
p70(S6K) and increased the proliferative response of these 
cells to doxorubicin [371]. Furthermore, treatment of mice 
bearing the PTEN-negative prostate cancer xenografts with 
CCI-779, an ester of rapamycin combined with doxorubicin, 
inhibited the growth of the doxorubicin-resistant tumors con-
firming the observations in vitro [371]. Thus, rapamycin and 
CCI-779, by interacting with downstream intermediates in 
the PI3K/Akt signaling pathway, reverse the resistance to 
doxorubicin conferred by PTEN mutation/Akt activation 
[371]. Another study examined the possible mechanisms of 
resistance to the EGFR inhibitor ZD1839 (Iressa) in tumor 
cells with variable levels of EGFR [372]. The results sug-
gested that loss of PTEN, by permitting a high level of Akt 
activity independent of RTK inputs, can temporally dissoci-
ate the inhibition of the EGFR with that of Akt induced by 
EGFR inhibitors [372]. Thus, it was suggested that in EGFR-
expressing tumor cells with concomitant amplification(s) of 
PI3K/Akt signaling, combined blockade of the EGFR tyro-
sine kinase and Akt should be considered as a therapeutic 
approach [372]. In another study, sensitivity to ZD1839 re-
quired intact growth factor receptor-stimulated Akt signaling 
activity. PTEN loss leads to uncoupling of this signaling 
pathway and results in ZD1839 resistance, which could be 
reversed with reintroduction of PTEN or pharmacologic 
down-regulation of constitutive PI3K/Akt pathway activity 
[373]. 
  In myeloma, PI3K inhibitors preferentially suppressed 
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cating that PI3K activation is more critical for growth and 
survival of those lines with PTEN mutations than others ex-
pressing a functional PTEN gene [374]. Expression of an 
active Akt, reversed wortmannin- and dexamethasone-
induced apoptosis and growth inhibition in PTEN-null mye-
loma lines, suggesting that Akt lies downstream of PI3K for 
PTEN-null myeloma survival and dexamethasone resistance 
[374]. 
  The ErbB2-targeting antibody, trastuzumab (Herceptin), 
has remarkable therapeutic efficacy in certain patients with 
ErbB2-overexpressing tumors. The overall trastuzumab re-
sponse rate for reasons that are not completely understood. It 
was reported that PTEN activation contributes to trastuzu-
mab's antitumor activity. Reducing PTEN in breast cancer 
cells by antisense oligonucleotides conferred trastuzumab 
resistance  in vitro and in vivo [375]. Patients with PTEN-
deficient breast cancers had significantly poorer responses to 
trastuzumab-based therapy than those with normal PTEN 
[375]. Additionally, PI3K inhibitors rescued PTEN loss-
induced trastuzumab resistance [375]. Thus, PTEN defi-
ciency was proposed to be a predictor for trastuzumab resis-
tance [375].  
  Forkhead family of transcription factors (FOXO1a, 
FOXO3a, FOXO4) are downstream targets of the 
PI3K/PTEN/Akt pathway. In PTEN null cells, FOXO1a is 
inactivated by PI3K-dependent phosphorylation and mislo-
calization to the cytoplasm, yet still undergoes nucleocyto-
plasmic shuttling. Since forcible localization of FOXO1a to 
the nucleus can reverse tumorigenicity of PTEN null cells, a 
high-content, chemical genetic screen for inhibitors of 
FOXO1a nuclear export was performed [376]. The com-
pounds detected in the primary screen were retested in sec-
ondary assays, and structure-function relationships were 
identified. Novel general export inhibitors were found that 
react with CRM1 as well as a number of compounds that 
inhibit PI3K/Akt signaling, among which are included mul-
tiple antagonists of calmodulin signaling [376]. 
Interactions with Other Tumor Suppressor Pathways 
  The PTEN tumor suppressor protein inhibits PI3K/Akt 
signaling that promotes translocation of Mdm2 into the nu-
cleus [195, 377]. When restricted to the cytoplasm, Mdm2 is 
degraded [377]. The ability of PTEN to inhibit the nuclear 
entry of Mdm2 increases the cellular content and transactiva-
tion of the p53 tumor suppressor protein. Retroviral trans-
duction of PTEN into PTEN null glioblastoma cells increases 
p53 activity and expression of p53 target genes and induces 
cell cycle arrest [378]. U87MG/PTEN glioblastoma cells 
were more sensitive than U87MG/PTEN null cells to death 
induced by etoposide, a chemotherapeutic agent that induces 
DNA damage [378]. These results established a direct con-
nection between the activities of two major tumor suppres-
sors and show that they act together to respond to stresses 
and malignancies. PTEN protects p53 from survival signals, 
permitting p53 to function as a guardian of the genome [377, 
378]. 
Mutations in Other Inositol Lipid Phosphatases 
  The SH2 domain-containing inositol 5'-phosphatase 
(SHIP) is crucial in hematopoietic developement. A somatic 
mutation at codon 684, replacing Val with Glu, was detected 
in one acute myeloid leukemia AML patient, lying within the 
signature motif 2, which is the phosphatase active site [379]. 
The results of an in vitro inositol 5'-phosphatase assay re-
vealed that the mutation reduced catalytic activity of SHIP 
[379]. Leukemia cells with the mutation showed enhanced 
Akt phosphorylation following IL-3 stimulation [379]. K562 
cells transfected with the mutated SHIP-V684E cDNA 
showed a growth advantage even at lower serum concentra-
tions and resistance to apoptosis induced by serum depriva-
tion and exposure to etoposide [379]. These results suggest a 
possible role of the mutated SHIP gene in the development 
of acute leukemia and chemotherapy resistance through the 
deregulation of the PI3K/Akt signaling pathway [379]. This 
was the first report of a mutation in the SHIP gene in any 
given human cancer, and indicates the need for more atten-
tion to be paid to this gene with respect to cancer pathogene-
sis [379].  
THE HUMAN PIK3CA ONCOGENE 
Increases in PIK3CA Copy Numbers 
  Studies using comparative genomic hybridization (CGH) 
revealed several regions of recurrent, abnormal, DNA se-
quence copy number that may encode genes involved in the 
genesis or progression of ovarian cancer [380]. One region at 
3q26 found to be increased in copy number in approximately 
40% of ovarian and others cancers contains PIK3CA, which 
encodes the p110 catalytic subunit of PI3K [380]. PIK3CA 
was shown to be frequently increased in copy number in 
ovarian cancers, and the increased copy number is associated 
with increased PIK3CA transcription, p110 protein expres-
sion and PI3K activity and the treatment with the PI3K in-
hibitor LY294002 decreased proliferation and increases 
apoptosis [380]. These observations suggested PIK3CA is an 
oncogene that has an important role in ovarian cancer [380]. 
In a subsequent study, PIK3CA mRNA was detected in 
66.6% of stage I and 93.9% of advanced stage ovarian can-
cer specimens and in all ovarian cancer cell lines [381]. 
PIK3CA mRNA levels were significantly higher in invasive 
carcinomas compared with benign and low malignant poten-
tial neoplasms [381]. Strong expression of immunoreactive 
p110 was detected in tumor cells and/or stroma endothe-
lium [381]. PIK3CA expression in vivo positively correlated, 
both at the mRNA and the protein level, with the expression 
of VEGF as well as with the extent of microvascular devel-
opment [381]. Furthermore, PIK3CA mRNA over-
expression positively correlated with increased proliferation 
and decreased apoptosis of tumor cells in vivo [381]. In vitro, 
PIK3CA expression positively correlated with the expression 
of VEGF in ovarian cancer cells, whereas LY294002 re-
duced both the constitutive and inducible expression of HIF-
1 at the mRNA and protein levels and abrogated VEGF up-
regulation by glucose starvation [381]. Furthermore, 
LY294002 suppressed cell proliferation and, at higher doses, 
induced marked apoptosis in ovarian cancer cells. Collec-
tively, these data strongly indicate that PIK3CA supports 
ovarian cancer growth through multiple and independent 
pathways affecting cell proliferation, apoptosis and angio-
genesis, and plays an important role in ovarian cancer pro-
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  The results of CGH also showed that the 3q26.3 amplifi-
cation was the most consistent chromosomal aberration in 
primary tissues of cervical carcinoma, and a positive correla-
tion between an increased copy number of PIK3CA and 
3q26.3 amplification was found in tumor tissues and in cer-
vical cancer cell lines [382]. In cervical cancer cell lines har-
boring amplified PIK3CA, the expression of p110 was in-
creased, and was subsequently associated with high kinase 
activity [382]. These evidences supported that PIK3CA is an 
oncogene in cervical cancer and PIK3CA amplification may 
be linked to cervical tumorigenesis [382]. In low-grade head 
and neck squamous cell carcinomas PIK3CA was over-
represented, as analyzed by CGH or fluorescence in situ hy-
bridization [383]. These results indicated that PIK3CA may 
participate to the progression of head and neck tumors [383]. 
  In another study, PIK3CA was identified as an oncogene 
involved in squamous cell carcinomas [384]. Simultaneous 
abnormalities in both pathways were rare in primary tumors, 
suggesting that amplification of PIK3CA and mutation of 
p53 are mutually exclusive events and either event is able to 
promote a malignant phenotype [384]. Moreover, the nega-
tive effect of p53 induction on cell survival involved the 
transcriptional inhibition of PIK3CA that was independent of 
PTEN activity, as PTEN was not expressed in the primary 
tumors [384]. Conversely, constitutive activation of PIK3CA 
resulted in resistance to p53-related apoptosis in PTEN defi-
cient cells [384]. Thus, p53 regulates cell survival by inhibit-
ing the PI3K/AKT prosurvival signal independent of PTEN 
in epithelial tumors. This inhibition is required for p53-
mediated apoptosis in malignant cells [384]. 
  Array CGH was used to identify genomic abnormalities 
at loci encoding genes that may contribute to lung cancer 
transformation and progression in squamous carcinomas 
(SqCas) and adenocarcinomas (AdCas) [385]. The most no-
ticeable differences between SqCas and AdCas were gain of 
chromosome 3q22-q26 and loss of chromosome 3p [385]. 
These occurred almost exclusively in SqCas and the region 
of recurrent increase contained PIK3CA [385]. The activity 
of Akt was higher in SqCas than in AdCas and was corre-
lated with PIK3CA copy number, suggesting that these copy 
number increases contribute to activation of PI3K signaling 
in SqCas of the lung [385]. In head and neck squamous cell 
carcinoma (HNSCC) a study suggested that 3q26 copy num-
ber gain and amplification represent early genomic aberra-
tions in HNSCC carcinogenesis [386]. In addition, p110 
mRNA and protein expression in HNSCC may be regulated 
by these genomic aberrations as well as by epigenetic events 
[386]. 
Discovery of Somatic Mutations in PIK3CA 
  To determine if PI3Ks are genetically altered in tumor- 
igenesis,
 the PI3K genes were sequenced in human cancers 
and corresponding normal
 tissue [387].
 Eight PI3K and eight
 
PI3K-like genes, including two uncharacterized genes, were 
identified in the
 human genome [387]. The sequences
 of 117 
exons that encode the predicted kinase domains of these
 
genes were examined in 35 colorectal cancers [387]. 
PIK3CA was the only gene with somatic (i.e.,
  tumor-
specific) mutations [387]. Subsequent sequence analysis of 
all
 coding exons of PIK3CA in 199 additional colorectal can-
cers
 revealed mutations in a total of 74 tumors (32%). The 
authors also evaluated 76 premalignant colorectal
 tumors and 
found only two mutations [387]. Thus,
  PIK3CA mutations 
generally arise late in tumorigenesis, just
 before or coinci-
dent with invasion. Mutations in PIK3CA were also identi-
fied in glioblastoma, gastric cancer, breast cancer and lung 
cancer [387]. In total, 92 mutations were observed, all of 
which were determined
  to be somatic in the cancers that 
could be assessed [387].
 No truncating mutations
 were ob-
served and >75% of alterations occurred in two small
 clus-
ters in the helical and kinase domains [387] (Fig. 2). The 
affected residues within these clusters are highly
 conserved 
evolutionarily. The lipid kinase activity of wild-type p110 
or a "hot-spot"
 mutants (H1047R) (Fig. 2) were measured. 
Expression of mutant p110
  conferred more lipid kinase 
activity than expression of wild-type
  protein [387].
  These 
data suggested that mutant PIK3CA was likely to function as
 
an oncogene in human cancers [387, 388]. This idea is con-
sistent with previously
 reported alterations of members of the 
PI3K pathway, particularly
 inactivation of the PTEN tumor 
suppressor [388]. This study found no























Fig. (2). Schematic of PIK3CA structure and “hot-spot” muta-
tions observed in human cancers. Cancer-specific mutations are 
clustered in the helical and catalytic domain of p100. Several mu-
tations have been reported in human solid tumors for PIK3CA, the 
gene that encodes the catalytic subunit p110 of PI3K. High fre-
quency of missense mutations is observed at the amino acid resi-
dues E542, E545 and H1047. The Phosphoinositide 3-Kinase Pathway in Human Cancer  Current Genomics, 2007, Vol. 8, No. 5    287 
gene amplification in 96 colorectal cancers,
 suggesting that 
amplification is not a common mechanism of activation
 in 
this tumor type [387]. A subsequent study analysed 340 
genes coding for serine/threonine kinases in colorectal 
tumours [389]. A total of 23 changes, including a majority 
(20) of non-synonymous point mutations were identified 
[389]. The gene mutations affected eight different proteins, 
including PDK1 (3 mutations out of which two mutations 
affected the same residue in the kinase domain) and Akt2 (2 
mutations) [389]. Eighteen of the 23 somatic mutations 
occurred at evolutionarily conserved residues in the genes 
encoding the serine/threonine kinases [389].  
Clinical Findings Related to PIK3CA Mutations 
  A large-scale mutational analysis of the helical and cata-
lytic domains of PIK3CA was performed in brain tumors 
[390]. A total of 13 mutations of PIK3CA within these spe-
cific domains were identified in anaplastic oligodendroglio-
mas, anaplastic astrocytomas, glioblastoma multiforme, and 
medulloblastomas, whereas no mutations were identified in 
ependymomas or low-grade astrocytomas [390]. These ob-
servations implicated PIK3CA as an oncogene in a wider 
spectrum of adult and pediatric brain tumors and suggested 
that PIK3CA may be a useful diagnostic marker or a thera-
peutic target in these cancers [390]. 
  Another group screened a large panel of primary human 
tumors for mutations in all coding exons of PIK3CA [391]. 
A strong proportion of primary breast cancers (40%) har-
bored mutations in PIK3CA, which were not associated with 
histologic subtype, estrogen receptor status, grade or pres-
ence of tumor in lymph nodes [391]. Among the primary 
epithelial ovarian cancers only 6.6% contain somatic muta-
tions, but there was a clear histologic subtype bias in their 
distribution [391]. Only a minority (2.3%) of serous carci-
nomas had PIK3CA mutations compared with 20.0% of en-
dometrioid and clear cell cancers. In contrast, PIK3CA gene 
amplification (>7-fold) was common among all histologic 
subtypes and was inversely associated with the presence of 
mutations [391]. Overall, PIK3CA mutation or gene amplifi-
cation was detected in 30.5% of all ovarian cancers and 45% 
of the endometrioid and clear cell subtypes [391]. In ad-
vanced ovarian carcinomas, activating PIK3CA missense 
mutations were found in only about 4% of the cases [392]. 
Somatic missense mutations in PIK3CA were observed in 
12% of ovarian carcinomas, and in 18% breast carcinomas in 
[393]. Another study reported PIK3CA somatic mutations in 
hepatocellular carcinomas (35.6%), breast carcinomas 
(26.9%), gastric carcinomas (6.5%), acute leukemias (1.1%) 
and non-small-cell lung cancers (1.3%) [394]. Some of the 
PIK3CA mutations were detected in the early lesions of 
breast cancer carcinoma, hepatocellular carcinoma, and gas-
tric carcinomas, suggesting that PIK3CA mutation may occur 
independent of stage of the tumors [394]. PIK3CA mutations 
were identified in 26% of human breast tumor samples and 
cell lines at about equal frequency in tumor stages I to IV in 
another study [395]. A highly significant association be-
tween  PIK3CA mutations and retention of PTEN protein 
expression was observed. In addition, PIK3CA mutations 
were associated with expression of estrogen and progester-
one receptors, lymph node metastasis, and ErbB2 overex-
pression. The fact that PIK3CA mutations and PTEN loss 
were nearly mutually exclusive implied that deregulated 
PI3K signaling is critical for tumorigenesis in breast cancers 
and that loss of either PIK3CA or PTEN abrogates the selec-
tive pressure for targeting of the other gene. However, a sub-
sequent study found that PIK3CA and PTEN mutations in 
breast cancer were not mutually exclusive and correlated 
with similar prognostic factors [396]. Intriguingly, PIK3CA 
mutations predicted for longer local recurrence-free survival 
[396]. In thyroid cancer, non-synonymous somatic mutations 
in  PIK3CA were found in anaplastic thyroid carcinomas 
(23%) [397]. In endometrial carcinoma, PIK3CA mutations 
occurred at high frequency (36%) as did the coexistence of 
PIK3CA/PTEN mutations (26%) [398]. PIK3CA mutations 
were more common in tumors with PTEN mutations (46%) 
compared with those without PTEN mutations (24%) [398]. 
In head and neck squamous cell carcinoma, mutations in 
PIK3CA were reported in 11% of the cases analysed [399]. 
Three of the four mutations (H1047R, E542K, E545K) had 
been previously reported as hotspot mutations [399]. In pan-
creatic cancer a recent study described PIK3CA mutations in 
a fraction (11%) of the specimens analysed and some of the 
somatic mutations were novel [400].  
Validation of PIK3CA as an Oncogene 
  The oncogenic potential of three of the most commonly 
observed PIK3CA mutations (E542K, E545K, H1047R) was 
investigated in chicken embryo fibroblasts [401]. All three 
mutants induced oncogenic transformation with high effi-
ciency [401]. The mutant-transformed cells displayed consti-
tutive phosphorylation of Akt, of p70(S6K), and of the 4E-
BP1 [401]. Rapamycin strongly suppressed cellular trans-
formation induced by the PI3K mutants, suggesting that 
TOR and its downstream targets are essential components of 
the transformation process [401]. It was also shown that 
three prevalent mutants of p110 are oncogenic in vivo 
[402]. The mutants induced tumors in the chorioallantoic 
membrane of the chicken embryo and caused hemangiosar-
comas in the animal [402]. These tumors were marked by 
increased angiogenesis and an activation of the Akt pathway 
[402]. The TOR inhibitor RAD001 blocked tumor growth 
induced by the H1047R p110 mutant [402]. In a subsequent 
study, all of eight PIK3CA mutations examined were shown 
increased p110 lipid kinase activity compared with the 
wild-type enzyme [403]. All the mutants strongly activated 
Akt and p70(S6K) and also induced morphologic changes, 
loss of contact inhibition, and anchorage-independent growth 
of NIH3T3 cells [403]. The hotspot mutations E542K, 
E545K, and H1047R, all had high enzymatic and transform-
ing activities [403]. These results showed that almost all the 
colon cancer-associated PIK3CA mutations are functionally 
active so that they are likely to be involved in carcinogenesis 
[403]. In a recent report, a panel of rare PIK3CA mutants 
was evalulated in chicken fibroblast tansformation assays, 
which also revealed their oncogenic potential and mecha-
nism of activation [404]. 
  To evaluate the consequences of PIK3CA alterations, the 
two most common mutations were inactivated by gene tar-
geting in colorectal cancer cells [405]. Biochemical analyses 
of these cells showed that mutant PIK3CA selectively regu-
lated the phosphorylation of Akt and of forkhead transcrip-
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growth under standard conditions, but reduced cellular de-
pendence on growth factors [405]. PIK3CA mutations re-
sulted in attenuation of apoptosis and facilitated tumor inva-
sion [405]. Importantly, treatment with LY294002 abrogated 
PIK3CA signaling and preferentially inhibited growth of 
PIK3CA mutant cells [405]. A recent study also showed that 
PIK3CA mutant colon cancer cell lines have increased me-
tastatic potential in an orthotopic model [406]. Two PIK3CA 
mutants observed in breast cancer (E545K and H1047R) 
were also tested in the MCF-10A immortalized breast epithe-
lial cell line [407]. Both variants displayed higher PI3K ac-
tivity than wild-type p110 yet remained sensitive to phar-
macologic PI3K inhibition [407]. In addition, expression of 
p110 mutants in mammary epithelial cells induced multiple 
phenotypic alterations characteristic of breast tumor cells, 
including anchorage-independent proliferation in soft agar, 
growth factor-independent proliferation, and protection from 
anoikis [407]. Expression of these mutant p110 isoforms 
also confered increased resistance to paclitaxel and induced 
abnormal mammary acinar morphogenesis in three-
dimensional basement membrane cultures [407]. 
  Another study compared the biochemical activity and 
transforming potential of mutant forms of p110 and p110 
in a human mammary epithelial cell system [408]. The two 
most common tumor-derived alleles of p110 (H1047R and 
E545K) potently activated PI3K signaling [408]. Human 
mammary epithelial cells expressing these alleles grew effi-
ciently in soft agar and as orthotopic tumors in nude mice 
[408]. A mutation in p110 homologous to the E545K allele 
of p110 was then constructed, but the resulting p110 mu-
tant was only weakly activated and induced minimal soft-
agar growth [408]. However, a gene fusion of p110 with a 
membrane anchor was highly active and transforming in 
both soft-agar and orthotopic nude mouse assays [408]. 
Work by another group investigated the oncogenic potential 
of all 4 catalytic class I PI3K isoforms [409]. At physiologi-
cal levels of expression, the wild-type p110 isoform lacked 
oncogenic potential, but gain-of-function mutations and 
overexpression of p110 were correlated with oncogenicity 
[409]. The p110, p110 and p110 isoforms induced trans-
formation of cultured cells as wild-type proteins, which 
could be suppressed by rapamycin [409]. The p110 isoform 
constitutively activated the Akt signaling pathway, but p110 
activated Akt only in the presence of serum [409]. The p110 
isoforms also differed in their requirements for upstream 
(Ras) signaling [409].  
ONCOGENIC MUTANTS OF THE p85 ADAPTOR  
  There exist several oncogenic mutants derived from the 
p85 adaptor. The first to be characterized was p65(PI3K), a 
mutant of the regulatory subunit of PI3K, which includes the 
initial 571 residues of the wild type p85-protein linked to a 
region conserved in the Eph tyrosine kinase receptor family. 
It was demonstrated that this mutation, obtained from a 
transformed cell, induces the constitutive activation of PI3K 
and contributes to cellular transformation [410]. It was 
shown that transgenic mice expressing in T lymphocytes 
p65(PI3K) developed an infiltrating lymphoproliferative 
disorder and autoimmune renal disease with an increased 
number of T lymphocytes exhibiting a memory phenotype 
and reduced apoptosis [411]. An oncogenic fusion product of 
the p85 subunit of PI3K and HUMORF8, a putative deu-
biquitinating enzyme was also described in a chronic mye-
loproliferative disorder [412]. Single-strand conformational 
polymorphism/heteroduplex analysis revealed the presence 
of somatic mutations in the gene for the p85 regulatory 
subunit of PI3K (PIK3R1) in primary human colon and ovar-
ian tumors and cancer cell lines [413]. All of the mutations 
lead to deletions in the inter-SH2 region of the molecule 
proximal to the Ser608 autoregulatory site [413]. Expression 
of a mutant protein with a 23 amino acid deletion leads to 
constitutive activation of PI3K providing the first direct evi-
dence that p85 is a new oncogene involved in human tu-
morigenesis [413]. A C-terminal truncated form of p85 was 
described in a human lymphoma cell line (CO) with a T cell 
phenotype derived from a patient with Hodgkin's disease 
[414]. As a result of a frame-shift mutation at amino acid 
636, p76 is lacking most of the C-terminal SH2 domain, but 
contains the inter-SH2 domain and is associated with an ac-
tive form of PI3K [414]. A PI3K-dependent constitutive ac-
tivation of Akt was detected in CO cells, which was only 
partially reduced after serum starvation [414]. Treatment of 
CO cells with the PI3K inhibitor wortmannin resulted in a 
concentration-dependent inhibition of cell proliferation asso-
ciated with an increased number of apoptotic cells [414].  
PI3K INHIBITORS AS ANTI-TUMOR AGENTS 
  Wortmannin and LY294002 were evaluated as potential 
anti-tumor agents in numerous studies starting in the mid-
nineties [415] and their ability to sensitizes tumor cells to 
chemotherapy and radiotherapy has been well documented 
[416]. The growth of Philadelphia chromosome (Ph)-positive 
leukemic cells was inhibited by wortmannin [417]. PI3K 
inhibition sensitized human tumor cells to the effects of ra-
diation [418]. Since wortmannin decreases the activities of 
both the ATM protein and DNA-PK, it was suggested that it 
might be of use as a sensitizing agent for radiotherapy and 
chemotherapy [121, 419]. The double-strand break signal-
ing/repair proteins ATM, ATR, and DNA-dependent protein 
kinase catalytic subunit (DNA-PK) are attractive targets to 
confer enhanced radio and chemosensitivity to tumor cells. 
Small interfering RNA (siRNA) targeting ATM and DNA-
PK gave rise to a significant dose-reduction factor compared 
at the clinically relevant radiation doses, which was greater 
than the radiosensitivity achieved using wortmannin or 
LY294002 [420]. A similar increased sensitivity to the alky-
lating agent methyl methanesulfonate (MMS) was also ob-
served for siRNA-mediated ATR silencing [420].  
  In Ewing's sarcoma family of tumors (ESFTs) the PI3K 
inhibitor wortmannin and LY294002 were evaluated in 
combination with chemotherapy [421]. Doxorubicin treat-
ment reduced cell number and enhanced apoptosis in PI3K 
inhibited cells compared with noninhibited cells [421]. In 
leukemia, the PI3K inhibitors LY294002 and wortmannin 
induced a significant increase in apoptosis in combination 
with cytotoxic drugs [422]. The PI3K/Akt pathway was 
shown to play a significant role in mediating drug resistance 
in human pancreatic cancer cells [423]. PI3K inhibitors were 
proposed to have therapeutic potential when combined with 
the chemotherapy agent gemcitabine in the treatment of pan-
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  Another report showed that cisplatin-induced DNA dam-
age causes the phosphorylation of BAD Ser-136 via a 
PI3K/Akt cascade and that inhibition of either of these cas-
cades sensitizes ovarian cancer cells to cisplatin [424]. Fur-
ther work suggested that paclitaxel induces the phosphoryla-
tion of BAD Ser-112 via the Erk cascade, and the phos-
phorylation of both BAD Ser-136 and Raf-1 Ser-259 via the 
PI3K/Akt cascade, and that inhibition of either of these cas-
cades sensitizes ovarian cancer cells to paclitaxel [425]. 
These observations were further developed in an in vivo 
model in [426]. LY294002 in combination with carboplatin 
was more effective in inhibiting ovarian cancer cell 
xenograft growth than either agent alone [426].  
  In breast cancer cell lines, Akt activity was constitutive 
and was associated with either PTEN mutations or ErbB2 
over-expression [427]. When combined with therapies com-
monly used in breast cancer treatment, LY294002 potenti-
ated apoptosis caused by doxorubicin, trastuzumab, pacli-
taxel, or etoposide [427]. Potentiation of apoptosis by 
LY294002 correlated with induction of Akt by doxorubicin 
or trastuzumab alone that occurred before the onset of apop-
tosis [427]. To determine a causal relationship between the 
activity of Akt and radioresistance in human breast cancer 
cells, MCF7 cells, transfected with constitutively active H-
Ras (RadG12V) or constitutively active Akt, were chosen for 
analysis in [428]. The results from this study indicated that 
the expression of constitutively active Ras and the expres-
sion of constitutively active Akt each increased cellular re-
sistance to radiation [428]. Inhibition of PI3K with LY294002 
reverted the constitutively active Ras-mediated radioresis-
tance, but not the constitutively active Akt-mediated radiore-
sistance [428]. These data suggested that Akt may be a po-
tential target for enhancing the response to radiotherapy in 
patients with breast cancer [428]. Another study showed the 
ErbB2/P13K/Akt pathway plays a role in mediating multi-
drug resistance in human breast cancer cells [429]. It was 
found that cell lines that express both ErbB2 and ErbB3 ap-
pear to have a higher phosphorylation level of Akt [429]. 
Transfection of ErbB2 in MCF7 breast cancer cells that ex-
press ErbB3 caused a PI3K-dependent activation of Akt, and 
was associated with an increased resistance of the cells to 
multiple chemotherapeutic agents (paclitaxel, doxorubicin, 
5-fluorouracil, etoposide, and camptothecin) [429]. Selective 
inhibition of PI3K or Akt activity with their respective domi-
nant-negative expression vectors sensitized the cells to the 
induction of apoptosis by the chemotherapeutic agents [429]. 
  Another study reported constitutive Akt phosphorylation 
(on Ser473) consistent with pathway activation in human 
pancreatic carcinoma cell lines in vitro [430]. Exposure of 
the cells to wortmannin and LY294002 resulted in a dose-
dependent induction of apoptosis in six of seven of the cell 
lines that displayed constitutive Akt phosphorylation but not 
in either of the cell lines that did not [430]. Exposure of or-
thotopic pancreatic tumors to LY294002 resulted in dose-
dependent inhibition of tumor growth, and decreased perito-
neal and liver metastases, effects that were associated with 
an inhibition of Akt phosphorylation and increased apoptosis 
[430]. Furthermore, a suboptimal dose of LY294002 pro-
duced additive inhibition of tumor growth when combined 
with a suboptimal dose of gemcitabine [430]. A further re-
port demonstrated that PI3K/Akt signaling promotes SCLC 
growth, survival, and chemotherapy resistance [431]. A 
panel of SCLC cell lines was very sensitive to LY294002 
and the inhibitor potentiated the effect of low concentrations 
of etoposide in inhibiting growth and inducing apoptosis 
[431]. In AML, a HL-60 cell clone was isolated which was 
highly resistant to several drugs inducing apoptosis and to 
the differentiating chemical all-trans-retinoic acid (ATRA) 
[432]. The resistant clone displayed an activated PI3K/Akt 
pathway, with levels of PIP3 higher than the parental cells 
and increased levels of phosphorylated Akt1 [432]. Treat-
ment of the resistant cell clone with wortmannin or 
LY294002 reversed resistance to drugs [432]. Resistant cells 
over-expressing either dominant negative PI3K or dominant 
negative Akt1 became sensitive to drugs and ATRA [432]. A 
subsequent study investigated whether a HL-60 human leu-
kemia cell clone (named AR) with constitutively active Akt1 
was resistant to TRAIL [433]. Parental HL-60 cells were 
very sensitive to TRAIL and died by apoptosis, while AR 
cells were resistant to TRAIL. LY294002 and wortmannin 
restored TRAIL sensitivity of AR cells [433]. Another study 
investigated the molecular mechanisms by which drug resis-
tance develops in human prostate cancer cells with a subline 
selected for resistance to camptothecin [434]. Expression 
differences were found in apoptosis-related genes in the di-
rection expected on the basis of the apoptosis-resistance for 
BAD, caspase-6, and genes that signal via the Akt pathway 
[434]. Exposure of the cells to wortmannin provided func-
tional support for involvement of the Akt pathway [434]. 
  Another study demonstrated synergistic augmentation of 
the cytotoxicity by LY294002 occurs specifically with an-
timicrotubule agents, at least partially through an increase in 
caspase 3-dependent apoptosis, and suggested that inhibitors 
of the PI3K/Akt pathway in combination with antimicrotu-
bule agents may induce cell death effectively and be a potent 
modality to treat patients with malignant gliomas [435]. 
  Cells transformed by oncogenic Ras, display a radioresis-
tant phenotype in response to ionizing radiation (IR). The 
PI3K inhibitor LY294002 radiosensitized cells bearing mu-
tant Ras, but the survival of cells with wild-type Ras was not 
affected [436]. In another study, the mechanisms by which 
Ras mediates radioresistance in epithelial cells were assessed 
[437]. The importance of three major survival pathways that 
can be activated by Ras (PI3K/Akt, NF-B, and Raf/MEK/ 
Erk) were investigated as necessary or sufficient for Ras-
mediated radioresistance in matched pairs of epithelial cells 
expressing oncogenic Ras or empty vector [437]. Inhibiting 
PI3K with LY294002 sensitized cells expressing oncogenic 
Ras to IR, indicating that PI3K is necessary for Ras-
mediated radioresistance [437]. Another study suggested that 
a combination of the PI3K inhibitor LY294002 and conven-
tional chemotherapy (paclitaxel) may provide an effective 
approach to inhibiting tumor growth and ascites production 
in ovarian cancer with acceptable side effects [438]. 
LY294002 demonstrated a growth-inhibitory and apoptosis-
inducing effect in colon cancer cell lines, with decreased 
expression of phosphorylated Akt [439]. In experiments us-
ing mouse xenografts, it was found that LY294002 admini-
stration in vivo also resulted in suppression of tumor growth 
and induction of apoptosis [439]. Resistance to conventional 
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well documented in malignant gliomas. In vitro, an actual 
antagonistic effect between sequential administration of ra-
diation and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) 
chemotherapy in primary human glioblastoma cell lines was 
observed, which was abrogated upon inhibition of EGFR 
with the a tyrosine kinase inhibitor [440]. It was found that 
BCNU inhibited radiation-induced apoptosis through EGFR-
mediated activation of PI3K/Akt via Ras [440].  
  Several reports have suggested an involvement of the 
Ras/PI3K/Akt signalling pathways in controlling multidrug 
resistance. It was found found cotreatment of drug-resistant 
colon cancer cells with the topoisomerase inhibitor doxoru-
bicin and LY294002 resulted in massive apoptosis, suggest-
ing that the PI3K pathway controls cell survival and drug 
resistance in these cells [441]. LY294002 inhibited drug ex-
port in a competitive manner and the efficacy of drug efflux 
inhibition by LY294002 was similar to that achieved by 
MRP1 inhibitors [441]. 
  Further work provided the first evidence that the sys-
temic administration of a PI3K inhibitor LY294002 has anti-
tumor and antiangiogenic activity in vivo [442]. It was 
shown that PTEN reconstitution diminished phosphorylation 
of Akt, induced the transactivation of p53 and increased the 
expression of p53 target genes in glioma cells [442]. PTEN 
and LY294002 induced p53 activity in human brain endothe-
lial cells, suggesting that PTEN and PI3K pathways can sup-
press the progression of cancer through direct actions on 
tumor and endothelial cells [442]. LY294002 inhibited 
glioma tumor growth in vivo, induced tumor regression, de-
creased the incidence of brain tumors, and blocked the tu-
mor-induced angiogenic response in vivo [442]. These data 
provided evidence that both PTEN and PI3K inhibitors regu-
late p53 function and display in vivo anti-angiogenic and 
anti-tumor activity [442]. These results provided evidence 
that the two tumor suppressor genes, PTEN and p53, act to-
gether to block tumor progression in vivo. LY294002 inhib-
ited ascites formation in a mouse model of human ovarian 
cancer by inhibiting tumor and peritoneal neovascularization 
as well as vascular permeability [443]. LY294002 also di-
rectly inhibited VEGF protein expression and release from 
ovarian carcinoma, suggesting that the inhibitor blocks the 
VEGF signaling pathway involved in angiogenesis and vas-
cular permeability [443]. 
  Topical treatment with inhibitors of the PI3K/Akt and 
Raf/mitogen-activated protein kinase kinase/extracellular 
signal-regulated kinase pathways inhibited the growth of 
TPras transgenic melanomas in severe combined immunode-
ficient mice, blocked invasive behavior, and reduced angio-
genesis [444]. The inhibitor LY294002 effectively reduced 
melanoma cell growth both in vitro and in vivo [444]. Both 
LY294002 and U0126, a MEK 1/2 inhibitor, reduced inva-
sion, which correlated with reduction of the metalloprotein-
ase matrix metalloproteinase 2 [444]. Tumor angiogenesis 
was disrupted through inhibition of VEGF production from 
the tumor cells and antiangiogenic effects on endothelial 
cells [444]. 
  STI571 (Gleevec), an anti-leukemia drug targeting 
BCR/ABL kinase can induce remissions of the Ph(1)-
positive leukemias (CML). The anti- Ph(1)-leukemia effect 
of the combination of BCR/ABL kinase inhibitor STI571 
and PI3K inhibitors wortmannin or LY294002 was tested in 
[445]. It was shown that STI571 and wortmannin exerted a 
synergistic effect against the Ph(1)-positive cell lines, but did 
not affect the growth of Ph(1)-negative cell line [445]. 
Moreover, the combinations of STI571 and wortmannin or 
STI571 and LY294002 were effective in the inhibition of 
clonogenic growth of CML-chronic phase and CML-blast 
crisis patient cells, while sparing normal bone marrow cells 
[445].  
  In addition, novel PI3K inhibitors have been described, 
that may be more potent than LY294002 or wortmannin. For 
example, ZSTK474 has recently been described as a new 
PI3K inhibitor with strong antitumor activity against human 
cancer xenografts without toxic effects in critical organs 
[446].  
  The potential of deguelin, a natural plant product, as a 
lung cancer chemopreventive agent was investigated in 
[447]. Deguelin treatment inhibited the growth of and in-
duced apoptosis of premalignant and malignant human bron-
chial epithelial (HBE) cells, but had minimal effects on nor-
mal HBE cells [447]. Levels of phosphorylated Akt (pAkt) 
were higher in premalignant HBE cells than in normal HBE 
cells [447]. In premalignant HBE cells, deguelin inhibited 
PI3K activity and reduced phosphorylated Akt levels and 
activity. A constitutively active Akt in premalignant and 
malignant HBE cells blocked deguelin-induced growth arrest 
and apoptosis [447]. Because both premalignant and malig-
nant HBE cells are more sensitive to deguelin than normal 
HBE cells, deguelin may have potential as both a chemopre-
ventive agent for early stages of lung carcinogenesis and a 
therapeutic agent against lung cancer [447]. In AML, a fur-
ther study showed that deguelin induced cell cycle arrest and 
increased apoptotic cell death [448]. Deguelin also down-
regulated Akt phosphorylation of leukaemia cells and mark-
edly increased sensitivity of U937 cells to etoposide or cyta-
rabine [448]. 
ISOFORM-SPECIFIC PI3K INHIBITORS 
  There is extensive evidence from the molecular and ge-
nomic analysis of human cancers presented above that the 
PI3K/Akt pathway is deregulated in malignant progression 
[449]. Furthermore, the causal involvement of PI3K is sup-
ported by gene-knockout mouse models. Prototype inhibitors 
such wortmannin and LY294002 have show evidence of 
anticancer activity in vitro and in vivo animal models. There-
fore, the recent development of isoform-selective inhibitors 
shows considerable promise for cancer treatment [450-452].  
  To determine the contribution of the hemopoietic cell-
restricted p110 in neutrophil chemotaxis, a potent and se-
lective p110 inhibitor, IC87114 was developed [453, 454]. 
IC87114 inhibited polarized morphology of neutrophils, 
fMLP-stimulated PIP3 production and chemotaxis [453]. 
Isoform-selective PI3K p110 inhibitors were developed, 
which prevented formation of stable integrin (IIb)(3) ad-
hesion contacts in platelets, leading to defective platelet 
thrombus formation [455]. A new generation of isoform-
selective class I PI3K inhibitors was used to show that reac-
tive oxygen species production in neurophils is regulated by 
temporal control of class I PI3K activity [456]. Further stud-
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selective and orally active small-molecule inhibitors of 
p110 with activity in mouse models of rheumatoid arthritis 
[457]. A chemically diverse panel of PI3K inhibitors was 
synthesized and evaluated in a recent study [458]. It was 
found that p110 is the primary insulin-responsive PI3K in 
cultured cells, whereas p110 was dispensable, but set a 
phenotypic threshold for p110 activity. Compounds target-
ing p110 impaired the acute effects of insulin treatment in 
vivo [458]. Intriguingly, these results corroborated the find-
ings from a study using a knock-in mouse with a catalyti-
cally-inactive p110 [459]. 
  In a first study in human cancer, a large panel of tissues 
and cell lines were screened for expression of class IA PI3Ks, 
which documented a ubiquitous expression of the p110 and 
p110 isoforms but a variable and more restricted tissue dis-
tribution of the p110 isoform [460]. Originally found in 
leukocytes, p110 was also detected in some nonhema-
topoietic cell types especially those of breast or melanocytic 
origin, both in the untransformed and transformed state 
[460]. Isoform-specific neutralization of PI3K isoforms in 
breast cancer cell lines, by PI3K antibody microinjection or a 
p110-selective pharmacological inhibitor, demonstrated that 
p110 is the most important class IA PI3K in the regulation 
of epidermal growth factor-driven motility in vitro, control-
ling the directionality and, to a lesser extent, the speed of 
migration [460]. In contrast, p110 was required for the di-
rection but not the speed of migration, whereas p110 did 
not impact on either of these parameters [460]. These results 
showed a nonredundant function of PI3K isoforms down-
stream of the epidermal growth factor receptor and indicate 
that the presence of p110 may confer breast cancer cells 
with selective migratory capacities [460]. 
 The  p110 isoform was shown to be expressed in endo-
thelial cells [461]. The p110 specific inhibitor IC486068 
abrogated radiation-induced phosphorylation of Akt. 
IC486068 enhanced radiation-induced apoptosis in endothe-
lial cells and reduced cell migration and tubule formation of 
endothelial cells in Matrigel following irradiation [461]. 
IC486068 enhanced radiation-induced endothelial cytotoxic-
ity, resulting in tumor vascular destruction and tumor control 
when combined radiotherapy in murine tumor models [461]. 
These findings suggest that p110 is a therapeutic target to 
enhance radiation-induced tumor control [461]. 
  It was shown that the p110 isoform is consistently ex-
pressed at a high level in blast cells from AML, in contrast to 
the other class I isoforms, the expression of which was very 
variable among patients [462]. The p110-selective inhibitor 
IC87114 suppressed both constitutive and Flt-3-stimulated 
Akt activation in blasts to the same extent as LY294002, an 
inhibitor of all PI3K isoforms. Moreover, IC87114 inhibited 
AML cell proliferation without affecting the proliferation of 
normal hematopoietic progenitor cells [462]. Thus, p110 
may represent a potential therapeutic target in AML. In a 
subsequent study, the combination of IC87114 and etopo-
side/VP16 was shown to be synergistic in reducing cell vi-
ability in AML, and was associated with a reduction in con-
stitutive NF-B activity [463].  
  Several other isoform-specific PI3K inhibitors have been 
developed in the past years. Biologically stable semisyn-
thetic viridins were developed as inhibitors of PI3K in [464]. 
The most active compound was termed PX-866 and is a 
PI3K inhibitor with selectivity for p110 [464]. Initial re-
sults showed that PX-866 is a biologically stable broad-
spectrum PI3K inhibitor with good pharmacokinetics that 
causes prolonged inhibition of PI3K signaling in human tu-
mor xenografts [464]. PX-866 exhibited single agent in vivo 
antitumor activity and increased the antitumor effects of cis-
platin and radiation treatment [464]. In a subsequent study, 
PX-866 was shown to potentiate the antitumor activity of 
gefitinib against NSCLC xenografts in vivo [465]. 
  In a recent study, one single agent (PI-103) induced 
proliferative arrest in glioma cells, despite the ability of 
many other compounds under study to block PI3K signaling 
through its downstream effector, Akt [466]. The unique cel-
lular activity of PI-103 could be attributed to its ability to 
inhibit both p110 and mTOR [466]. PI-103 showed signifi-
cant activity in tumors in vivo with no observable toxicity 
[466]. These data demonstrated an emergent efficacy due to 
combinatorial inhibition of mTOR and p110 in malignant 
glioma [466]. 
Akt INHIBITORS 
  A small molecule Akt pathway inhibitor, Akt/protein 
kinase B signaling inhibitor-2 (API-2) suppressed the kinase 
activity and phosphorylation level of Akt [467]. The inhibi-
tion of Akt kinase resulted in suppression of cell growth and 
induction of apoptosis in human cancer cells that harbor con-
stitutively activated Akt due to overexpression of Akt or 
other genetic alterations such as PTEN mutation [467]. API-
2 was highly selective for Akt and did not inhibit PI3K acti-
vation or other kinases [467]. Furthermore, API-2 potently 
inhibited tumor growth in nude mice of human cancer cells 
in which Akt is aberrantly expressed/activated but not of 
those cancer cells in which it is not [467].  
  Another report investigated the effects of small molecule 
inhibitors of Akt, which target the Akt PH domain and have 
isoform-specific activity [468]. In multiple cellular back-
grounds, maximal induction of caspase-3 activity, an indica-
tor of apoptosis, was achieved when both Akt1 and Akt2 
were inhibited [468]. It was also shown that in different tu-
mor cell backgrounds inhibition of mTOR was less effective 
in inducing caspase-3 activity than inhibition of Akt1 and 
Akt2 [468]. 
  A study examined whether Akt is required and sufficient 
to mediate brain-derived neurotrophic factor (BDNF)/TrkB 
protection of neuroblastoma cells from chemotherapy [469]. 
Pharmacologic inhibition of Akt, with PIA6, a phosphatidy-
linositol ether lipid analogue, blocks BDNF-induced phos-
phorylation of Akt and the downstream target of Akt [469]. 
PIA6 sensitizes neuroblastoma cells to chemotherapy and 
attenuates BDNF protection of neuroblastoma cells from 
chemotherapy-induced cell death [469]. 
  KP372-1, another Akt inhibitor, was evaluated in thyroid 
cancer cells [470]. Thyroid cancer consistently expresses 
phosphorylated Akt. KP372-1 blocked signalling down-
stream of Akt in thyroid tumour cells, leading to inhibition 
of cell proliferation and increased apoptosis [470]. In another 
study, KP-372-1 and KP-372-2 effectively inhibited the 
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more, the treatment of glioma cells with these inhibitors re-
sulted in the induction of apoptosis [471]. 
RAPAMYCIN AND RAPAMYCIN ANALOGS 
  The mammalian target of rapamycin (mTOR) has 
emerged as an important therapeutic target for cancer [472-
474]. Rapamycin and its derivatives that specifically inhibit 
mTOR are now being actively evaluated in clinical trials 
[472, 474]. However, many cancer cells are resistant to ra-
pamycin and its derivatives. The mechanism of this resis-
tance remains a subject of major therapeutic significance 
[475]. We will not discuss the potential of rapamycin and its 
derivatives in great detail here, in view of the many excellent 
reviews already published on the topic. 
  It was reported that the inhibition of mTOR by rapamy-
cin triggers the activation of two survival signaling pathways 
that may contribute to drug resistance. Treatment of human 
lung cancer cells with rapamycin suppressed the phosphory-
lation of p70(S6K) and 4E-BP1, indicating an inhibition of 
mTOR signaling [476]. Paradoxically, rapamycin also con-
currently increased the phosphorylation of both Akt and 
eIF4E [476]. The rapamycin-induced phosphorylation of Akt 
and eIF4E was suppressed by LY294002, suggesting the 
requirement of PI3K in this process [476]. The activated Akt 
and eIF4E appeared to attenuate the growth-inhibitory ef-
fects of rapamycin, serving as a negative feedback mecha-
nism. In support of this model, rapamycin combined with 
LY294002 exhibited enhanced inhibitory effects on the 
growth and colony formation of cancer cells [476]. Further 
work suggested that feedback down-regulation of receptor 
tyrosine kinase signaling is a frequent event in tumor cells 
with constitutive mTOR activation [477]. Reversal of this 
feedback loop by rapamycin may attenuate its therapeutic 
effects, whereas combination therapy that ablates mTOR 
function and prevents Akt activation may have improved 
antitumor activity [477]. A recent report showed that that 
rapamycin mediates Akt activation through an IGF-IR-
dependent mechanism [478]. Thus, it was concluded that 
combinatorial targeting of mTOR and the IGF-IR may be a 
promising strategy to enhance mTOR-targeted anticancer 
therapy [478]. 
CONCLUSIONS AND PERSPECTIVES 
  Almost twenty years after the discovery of PI3K, this 
family of enzymes has become the focus of intensive re-
search aimed at developing new drugs for a wide variety of 
diseases, including cancer, inflammation and allergy. The 
discovery of the many genetic alterations affecting the 
PI3K/PTEN/Akt/mTOR pathway in human cancer has 
clearly placed some of the enzymes involved, including 
p110, mTOR and Akt, on the top list of druggable targets 
in the field on oncology research. Moreover, the recognition 
that some of the molecular alterations, such as increased Akt 
phosphorylation or PTEN mutations correlate with clinical 
parameters, such as outcome, in cancer patients will possibly 
result in the development of new diagnostic protocols in spe-
cific types of cancer. What are the challenges ahead? The 
generic PI3K inhibitors LY294002 and wortmannin have 
greatly facilitated the deciphering of the biological responses 
and signaling pathways controlled by PI3K and have even 
proved to be successful in a variety of pre-clinical models of 
human cancer. The new generations of pharmacological in-
hibitors with increased specificity for one or a restricted 
number of PI3K isoforms and related kinases are entering 
clinical trials. It has been demonstrated that combining these 
agents with receptor tyrosine kinase inhibitors, which have 
already been evaluated in clinical trials, can produce syner-
gistic effects in stopping tumor growth in a variety of pre-
clinical models. One can thus reasonably hope that these 
drug combinations will result in improved survival benefits 
for cancer patients. However, there remain many open ques-
tions related to the mechanisms governing sensitivity or re-
sistance of tumors to these targeted agents. The best exam-
ples of such open questions are rapamycin and its analogs. 
There are now several reports describing potential novel 
mechanisms of resistance to these agents and there may be 
even more to be discovered in the future. A central question 
in the field of isoform-specific PI3K inhibitors is the ques-
tion of specificity. The class IA PI3K catalytic isoforms have 
a high degree of sequence homology in their catalytic do-
mains and demonstrating the specificity of the cellular ef-
fects of these agents remains problematic, since there are no 
specific readouts that discriminate between these three en-
zymes. Moreover, assessing the exact expression pattern of 
all enzymes of the PI3K family in a given tumor sample re-
mains problematic, in view of the lack of availability of iso-
form-specific antibodies which can be used in immunohisto-
chemistry. Such information is in our opinion of great impor-
tance, since there exist, in addition to the well-studied class I 
PI3K isoforms, three class II enzymes, with still poorly un-
derstood cellular functions, at least in human cancer. In addi-
tion, the class III PI3K Vps34p should also be taken into 
account when designing future therapies based on targeting 
PI3K isoforms, in view of its roles in autophagy and intracel-
lular trafficking events. 
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